Antiviral Research 92 (2011) 389–407
Contents lists available at SciVerse ScienceDirect
Antiviral Research
journal homepage: www.elsevier.com/locate/antiviral
Review
NanobodiesÒ: New ammunition to battle viruses q
Peter Vanlandschoot a,⇑, Catelijne Stortelers a, Els Beirnaert a,1, Lorena Itatí Ibañez b,c, Bert Schepens b,c,
Erik Depla a, Xavier Saelens b,c
a
Ablynx NV, Technologiepark 21, B-9052 Ghent, Belgium
Department of Molecular Biomedical Research, VIB, Technologiepark 927, B-9052 Ghent, Belgium
c
Department of Biomedical Molecular Biology, Ghent University, Technologiepark 927, B-9052 Ghent, Belgium
b
a r t i c l e
i n f o
Article history:
Received 8 July 2011
Revised 30 August 2011
Accepted 6 September 2011
Available online 10 September 2011
Keywords:
Nanobody
Camelidae
Heavy chain-only antibody
VHH
Antiviral
a b s t r a c t
In 1989, a new type of antibody was identified, first in the sera of dromedaries and later also in all other
species of the Camelidae family. These antibodies do not contain a light chain and also lack the first constant heavy domain. Today it is still unclear what the evolutionary advantage of such heavy chain-only
antibodies could be. In sharp contrast, the broad applicability of the isolated variable antigen-binding
domains (VHH) was rapidly recognized, especially for the development of therapeutic proteins, called
NanobodiesÒ. Here we summarize first some of the unique characteristics and features of VHHs. These
will next be described in the context of different experimental therapeutic applications of Nanobodies
against different viruses: HIV, Hepatitis B virus, influenza virus, Respiratory Syncytial virus, Rabies virus,
FMDV, Poliovirus, Rotavirus, and PERVs. Next, the diagnostic application of VHHs (Vaccinia virus, Marburg virus and plant Tulip virus X), as well as an industrial application (lytic lactococcal 936 phage) will
be described. In addition, the described data show that monovalent Nanobodies can possess unique characteristics not observed with conventional antibodies. The straightforward formatting into bivalent, multivalent, and/or multispecific Nanobodies allowed tailoring molecules for potency and cross-reactivity
against viral targets with high sequence diversity.
Ó 2011 Published by Elsevier B.V.
Contents
1.
2.
3.
q
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Camelid antibodies and Nanobodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.1.
VHHs display high affinity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.2.
VHHs can recognize structures not recognized by or inaccessible for conventional antibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.3.
VHH are remarkably stable under different extreme conditions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.4.
Enhanced functionality by easy multimerization of VHHs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.5.
Alternative expression of Nanobodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Therapeutic applications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.1.
Influenza virus Nanobodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.2.
Respiratory Syncytial virus (RSV) Nanobodies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.3.
Rabies virus Nanobodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.4.
Poliovirus Nanobodies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.5.
Foot-and-mouth disease virus (FMDV) Nanobodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.6.
Rotavirus Nanobodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.7.
Human Immunodeficiency virus (HIV) Nanobodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.7.1.
HIV gp120 Nanobodies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.7.2.
HIV Rev Nanobodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.7.3.
HIV Nef Nanobodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.7.4.
CXCR4 Nanobodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
NanobodyÒ is a registered trademark of Ablynx NV.
⇑ Corresponding author. Tel.: +32 9 262 01 13; fax: +32 9 262 00 02.
1
E-mail address: Peter.Vanlandschoot@Ablynx.com (P. Vanlandschoot).
Present address: VIB headquarters, Rijvisschestraat 120, B-9052 Gent, Belgium.
0166-3542/$ - see front matter Ó 2011 Published by Elsevier B.V.
doi:10.1016/j.antiviral.2011.09.002
390
393
394
394
394
394
394
394
394
395
396
396
396
397
398
399
399
400
400
390
P. Vanlandschoot et al. / Antiviral Research 92 (2011) 389–407
3.8.
4.
5.
6.
Hepatitis B virus (HBV) Nanobodies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.8.1.
HBV S domain Nanobodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.8.2.
HBV nucleocapsid Nanobodies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.8.3.
Porcine endogenous retrovirus (PERV) Nanobodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Diagnostic applications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.1.
Vaccinia virus and Marburg virus VHHs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.2.
Plant virus VHHs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Industrial applications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5.1.
Lactococcus bacteriophage VHH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Disclosure statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1. Introduction
Billions of different antibody molecules are generated by the
vertebrate immune system. A specific antibody binding every
existing compound is thought to be present in this antibody repertoire. It is this unparalleled high diversity and selectivity that make
antibodies attractive and efficient research tools but also therapeutic molecules. Up to 1989, all antibodies were thought to be composed of two heavy chains and two light chains. The two heavy
chains are covalently linked by disulfide bonds. The heavy chains
of IgGs consist of 1 variable domain (VH) and 3 constant domains
called CH1, CH2 and CH3. The light chains consist of a variable (VL)
and constant domain (CL) that interact non-covalently with the VH
and CH1 domains, respectively (Fig. 1). In 1989, a new type of antibody was identified, first in the sera of dromedaries and later also
in all other species of the Camelidae family (Hamers-Casterman
et al., 1993). These antibodies do not contain a light chain and also
401
401
401
402
402
402
402
403
403
403
404
404
404
lack the first constant heavy domain. Today it is still unclear what
the evolutionary advantage of such heavy chain-only antibodies
(HcAbs) could be. In sharp contrast, the broad applicability of the
isolated variable antigen-binding domains (VHH) was rapidly recognized, especially for the development of therapeutic proteins
(for recent reviews see Harmsen and De Haard (2007), Van
Bockstaele et al. (2009), Muyldermans et al. (2009), Wesolowski
et al. (2009), and Kolkman and Law (2010)). Such therapeutic proteins based on the smallest functional fragments of heavy chain
antibodies, naturally occurring in Camelidae have been called
NanobodiesÒ. Another type of heavy chain-only antibodies was
found in sharks, the socalled immunoglobulin new antigen receptors (IgNARs) (Greenberg et al., 1996; Nuttall et al., 2001). The
antigen-binding variable domains of these antibodies (vNARs), as
wells as single-domain antibodies (dAbs) derived from human
variable heavy domains (VH) and variable light domains (VL) have
similar applications (Holliger and Hudson, 2005).
Fig. 1. Distinguishing structural features of conventional antibodies and camelid heavy-chain antibodies. Conventional IgG antibodies comprise of two heavy (H) chains and
two light (L) chains, and carry two antigen-binding sites determined by the combination of the variable domains of heavy and light chains (VH and VL). Camelid heavy-chain
antibodies lack both constant and variable light chains (CL and VL) and the first heavy chain constant (CH1) domain, and the antigen-binding site is formed only by the heavy
chain variable domain (VHH or Nanobody). VHHs are characterized by the presence of hydrophilic amino acid residues in the second framework region (FR2), the socalled
hallmark residues (indicated according to Kabat numbering). In many VHHs an additional disulfide bond is present connecting the first (camels) or second (llamas) with the
third complementary determining regions (CDRs).
Table 1
Overview of published camelid-derived Nanobodies directed against viruses.
References
Immunogen
Camelid
Producing host
Mechanism
In vitro data
Hultberg et al.
(2011)
HA (H5N1)
Llama
E. coli
Neutralization
Microneutralization IC50 0003–
7 nM. Neutralizing pseudotyped
MLV(H5) IC50: 1–150 nM
Influenza A
Ibañez et al.
2011)
HA (H5N1)
Llama
E. coli
Neutralization
RSV
Hultberg et al.
(2011)
Hultberg et al.
(2011)
Fusion protein
Llama
E. coli
G protein
Llama
E. coli
Thys et al.
(2010)
Harmsen
et al. (2007)
Type 1 Sabin
strain
Crude extract of
FMDV-infected
BHK cells
Dromedary
Llama
E. coli WK6
Neutralization
Yeast strain
VWK 18gal
Neutralization
VHHs neutralize FMDV O1
Manisa at concentrations below
0.34 mg/ml
FMDV
Harmsen
et al. (2008)
O1 Manisa/
Turkey/69 FMDV
Llama
Yeast strain
VWK 18gal
Neutralization
FMDV neutralization titer 1–
4 mg/l
FMDV
Harmsen
et al. (2009b)
O1 Manisa/
Turkey/69FMDV
Llama
Yeast strain
VWK 18gal
Neutralization
FMDV neutralization titer1–5 mg/
l
FMDV
Harmsen
et al. (2009a)
O1 Manisa/
Turkey/69 FMDV
Llama
Yeast strain
VWK 18gal
Neutralization
FMDV neutralization titer 0.008–
0016 mg/ml
Rotavirus
van der Vaart
et al. (2006)
G3 strains
Llama
Yeaststrain
VWK 18gal1
Neutralization
IC50 50 ng/ml
Rabies
Poliovirus
FMDV
In vivo data
Specificity
Observations
H5N1 (clade 1>clade
2.2>clade 2.5)
Prophylactic
Therapy: 0.5 lg/
mouse: lung virus
titers below the
detection limit.
Therapeutic: VHHb
4, 24 or 48 h after
challenge, higher
body weights and
lower lung virus
loads
IC50 bivalent: 0.1 nM; monovalent
250 nM
IC50 CVS-11 (genotype 1): 7,5–
325 nM; EBLV-1 (genotype 5):
012–586 nM
IC50 7–692 nM
H5N1
RSV Long (A) RSV B1 (B).
Antigenic site II
CVS-11 strain (genotype
1), street isolates, 5 EBLV1 strain; antigenic site IIa
Type 1 viruses
Passive transfer of
VHH did not protect
guinea pigs against
FMDV challenge
infection.
3 mg/kg of VHHs
(i.m.) reduce
viremia and viral
shedding but do not
prevent the
development of
FMDV clinical signs
or transmission.
VHHs reduce and
delay the
development of
clinical disease,
viraemia and viral
shedding; delay
FMD transmission.
GH-loop, FMDV type O1
Manisa
GH-loop, FMDV type O1
Manisa
FMDV O1 Manisa > FMDV
A Turkey > FMDV Asia 1
Shamir
GH-loop, FMDV type O1
Manisa
50–100 lg
significantly
reduced the number
of days with
diarrhea per pup
Porcine immunoglobulin
(pIg) binding VHHs
genetically fused to VHHs
against FMDV (100-fold
increased serum half-life)
Rotavirus G3 strains.
P. Vanlandschoot et al. / Antiviral Research 92 (2011) 389–407
Virus
Influenza A
Increase the FMDVneutralizing capacity of
two non-glycosylated
VHHs by genetic fusion to
another VHH that is
glycosylated.
A VHH has lost it’s
neutralizing capacity after
production in yeast.
(continued on next page)
391
Virus
References
Immunogen
Camelid
Producing host
Mechanism
In vitro data
In vivo data
Specificity
Observations
Rotavirus
Garaicoechea
et al. (2008)
Llama
E. coli TG1
Neutralization
0,2–15,6 lg/ml (concentration
that reduces > 80% of focus
forming units)
Partial protection
against rotavirus
diarrhea
Pant et al.
(2006)
Llama
Lactobacilli
paracasei
Neutralization
60 ng/ml reduce by 60% the
number of RRV-infected cells
Lower prevalence,
duration and
severity of diarrhea
Bovine rotavirus C486,
IND and B223, Human
rotavirus Wa; Equine
rotavirus H2.
G3 RRV strain
Broad neutralization
activity in vitro
Rotavirus
VP6 protein
derived from the
bovine rotavirus
c486 strain
G3 RRV strain
Rotavirus
Martín et al.
(2011)
G3 RRV strain
Llama
Neutralization
HIV-1
Forsman et al.
(2008)
Envelope
protein gp120
from HIV-1CN54
(subtype B/C)
Llama
L. paracasei
(coding
sequence
integrated in
bacterial
genome)
E. coli TG1
Neutralization
IC50 0.003 to 38 lg/ml
HIV-1 primary isolates of
subtypesB, C, and
CRF07_BC
HIV-1
Koh et al.
(2010)
Llama
E. coli TG1
Neutralization
IC50: Subtype B: 0,07–0,57 lg/ml;
Subtype C: 0,04–0,96 lg/ml
Subtypes B and C
HIV-1
Vercruysse
et al. (2010)
Envelope
protein gp120
from HIV-1CN54
(subtype B/C)
Recombinant
HIV-Rev protein
Llama
E. coli;
eucariotic cells
intrabody binds
the
multimerization
domain of Rev
and inhibits its
oligomerization.
0,2 lg of plasmid inhibit 50% of
p24 Gag amount in the
supernatants oftransfected cells
Intrabody-Rev interaction
is completely abolished
by the K20A and Y23A
mutations
HIV-1
Bouchet et al.
(2011)
Recombinant
Nef protein
(fragment 57–
205)
Llama
E. coli K12
strainTG1
VHH binds to
HIV-1 Nef and
inhibit its
critical biologic
activities
VHH inhibits virus infectivity in a
Nef-dependent mannerand
counteracts the positive effect of
Nef on virus replication
HIV-1
Jähnichen
et al. (2010)
CXCR4expressing
HEK293T cells
Llama
E. coli TG1
Monovalent
VHHs: neutral
antagonists,
biparatopic
VHHs: inverse
agonists
IC50 Monovalent: 13,6–82 mM;
Bivalent: 0,2–0,5 nM
HBV
Serruys et al.
(2009)
E. coli-derived
nucleocapsids
(HBcAg) and
plasma-purified
HBsAg
Llama
E. coli WK6;
HepG2 cells
VHHs were shownto
reduce the duration
and severity of
diarrhea
The concentration of
hbv dna in plasma
was reduced 10–
100-fold. The levels
of secreted hbeag
were not affected
Reconstituted freezedried VHH1-anchored
lactobacilli are equally as
protective as their fresh
counterparts. VHH1secreting lactobacilli do
not offer better protection
than contransformed
lactobacilli
Rotavirus G3 strains
First description of
broadly neutralizing
MAbs to HIV-1 envelope
which were derived from
an immunized animal
Construction of a Familyspecific Phage Display
Library
First known molecule that
destabilizes and prevents
the formation of a large
organized homoprotein
complex required for
efficientHIV-1 mRNA
export from the nucleus
VHH counteracts most of
the HIV-1 nef alleles
including Nef proteins
from groups M, N, O, and P
238D4: binds D187,F189,
E179, and S178 in ECL2;
238D2: binds F189, N192,
W195,P191,V196 and
E277 in ECL3. F189,
positioned in ECL2, is
critical for binding of both
VHHs
Envelope protein s
More than 1000-fold
selectivity of 238D2and
238D4 for CXCR4 versus
all other GPCRs tested
First report of intrabodymediated inhibition of
viral secretion in
mammals
P. Vanlandschoot et al. / Antiviral Research 92 (2011) 389–407
Suppress hbsag particle secretion
(80–90%) and increase hbsag
accumulation/retention inside
the cell.
VHH rescues Nefmediated thymic
CD4 T-cell
maturation defect
and peripheral CD4
T-cell activation
phenotypes of the
CD4C/HIV-1Nef Tg
mouse model
The biparatopic
nanobody
effectively
mobilized CD34positive stem cells
in cynomolgus
monkeys
392
Table 1 (continued)
P. Vanlandschoot et al. / Antiviral Research 92 (2011) 389–407
Here we summarize first some of the unique characteristics
and features of VHHs. These will next be described in the context
of different experimental therapeutic applications of Nanobodies
against different viruses: HIV, Hepatitis B virus, influenza virus,
Respiratory Syncytial virus, Rabies virus, FMDV, Poliovirus,
Rotavirus, and PERVs. Next, the diagnostic application of VHHs
(Vaccinia virus, Marburg virus and plant Tulip virus X), as well
as an industrial application (lytic lactococcal 936 phage) will be
described. All these different applications are summarized in
Table 1.
Receptor-binding protein
(RBP/ORF18) of Phage sk1,
phage p2.
L. lactis bacteriophage p2
Hultberg et al.
(2007)
Bacteriophage
Llama
L. paracasei
Neutralization
VHH prevent phage infection,
even at concentrationsas low as
2.25 nM
VHH-secreted neutralise phage
p2 by binding to its RBP and
inhibiting (86%) its adsorption to
the host strain. Surface expressed
VHH inhibit phage infection (31%)
E. coli and yeast
L. lactis bacteriophage p2
De Haard
et al. (2005)
Bacteriophage
Llama
E. coli TG1
Alpaca
TuVX particles
Beekwil-der
et al. (2008)
Marburg
Virus
2. Camelid antibodies and Nanobodies
Tulip virus X
E. coli
Tuner + pRARE
E. coli
Tuner + pRARE
Goldman
et al. (2006)
Sherwood
et al. (2007)
Vaccinia
Naieve
llama
Naieve
llama
Purified 60-kDa
Gagprotein
Dekker et al.
(2003)
Porcine
Retrovirus
Llama
E. coli TG1
Neutralization
Positive detection of virus
particles or diluted tulip leaf
extract
Tulip virus X
Diagnostic assays. First
recombinant antibody
specifically isolated for
any MARV protein
Diagnostic assay for
detection of the plant
pathogenic Tulip virus X
(TuVX)
Nucleoprotein (MARV
variants Musoke, Ravn,
and Angola)
Vaccinia
PERV-A and PERV-B
Cross-reativity HBcAg and
HBeAg (subtypes subtype
ayw and adw)
Competition assay: positive result
at ± 70 nm. Vhhs targeted to the
nucleus: elevated intracellular
amount of hbeag and absence of
hbcag in lysates
Intrabody reduces RT activity to
approximately 7% of the activity
in uninduced state.
Clones tested in ELISA are
vaccinia specific
The limit of detection 0.1–100
pfu/well.
E. coli WK6;
HepG2 cells
Llama
Recombinant
HBcAg
Serruys et al.
(2010)
HBV
393
Camelids produce conventional antibodies but they also produce heavy chain-only antibodies (HcAbs). In llama species
45% of serum antibodies are HcAbs, while in camelus species
this is 75% (Hamers-Casterman et al., 1993). In camelids, conventional antibodies are IgG1 isotypes, while IgG2 and IgG3 are
HcAbs (Fig. 1). Despite this abundance, which points to a significant role, there is little information on the functions and specificities of these HcAbs in immunity (Daley et al., 2010; Daley-Bauer
et al., 2010).
Because of a splice site mutation, heavy chain-only antibodies
lack the CH1 domain and also lack the complete light chain that
is partially anchored to the CH1 domain (Nguyen et al., 1999;
Woolven et al., 1999). The variable heavy-chain domains of HcAbs
(VHH) are generated form a V–D–JH gene rearrangement using a
separate set of 40 V gene segments, all related to the human
VH3 gene family (Harmsen et al., 2000; Nguyen et al., 2000). Different VHH subfamilies have been defined, but all share a few crucial
substitutions of germline-encoded amino acids Val37 ? Phe/Tyr,
Gly44 ? Glu/Gln, Leu45 ? Arg, and Trp47 ? Gly/Phe/Leu (Kabat
numbering), that increase the hydrophilicity of frame work 2
(FR2), the putative VH–VL interface (Fig. 1). These VHH hall mark
residues abrogate a possible interaction with VL domains and contribute to the stability, increased solubility and reduced aggregation tendency of HcAbs and VHHs compared to other single
domain antibodies (Hamers-Casterman et al., 1993; Muyldermans
et al., 1994; Vu et al., 1997). Remarkably the third complementary
determining region CDR3 of VHHs has been shown in many crystal
structures to fold back and cover the former VL interface, further
contributing to the stability and solubility of VHHs (Desmyter
et al., 1996; Muyldermans et al., 2001).
Compared to human VH domains, VHH often display a longer CDR3 loop (Muyldermans et al., 1994; Vu et al., 1997). This
leads to an increased surface area and repertoire that can interact with antigens. Such extended CDR3 loops are often stabilized by a disulfide bond between CDR1 and CDR3 or
between FR2 and CDR3. Nevertheless, a significant proportion
of VHH has a short CDR3 and lack the additional disulfide bond
(Vu et al., 1997; Harmsen et al., 2000). Increased binding diversity also results from non-canonical CDR1 and CDR2 loop structures and additional hotspots for somatic hyper mutation in the
CDR1 (Nguyen et al., 2000). Besides these VHH domains, VHHlike domains lacking the hall mark residues, the long CDR3
loops and the interloop disulfide bonds are also used in HcAbs
(Harmsen and De Haard, 2007). More recently it was suggested
that variable genes displaying a high degree of homology to the
human VH4 family add to the HcAb Ag-binding diversity
(Deschacht et al., 2010).
Because of these unique biophysical and biochemical features of
the antigen binding domains of HcAbs, VHH domains have been
produced recombinantly as separate entities (VHHs). This created
new possibilities and as such several (new) features and applications for VHH have been explored and described.
394
P. Vanlandschoot et al. / Antiviral Research 92 (2011) 389–407
2.1. VHHs display high affinity
VHHs against many different targets that include haptens, peptides, soluble and transmembrane proteins have been reported. Active immunization of dromedaries or llamas is most often used for
proteins and as a result VHHs with affinities in the lower nanomolar or even picomolar range have been reported (reviewed in
Harmsen and De Haard (2007), Van Bockstaele et al. (2009), Wesolowski et al. (2009), and Kolkman and Law (2010)). Considering the
monomeric nature of VHHs this is remarkable as these affinities
are in the same range of what is readily observed for conventional
bivalent antibodies. VHHs with nanomolar affinities have also been
obtained using naïve or synthetic libraries (Goldman et al., 2006;
Groot et al., 2006; Verheesen et al., 2006).
2.2. VHHs can recognize structures not recognized by or inaccessible
for conventional antibodies
Structural analysis of conventional antibodies and VHHs, in
complex with their antigen has revealed a major difference in
the structure of the CDRs. While conventional antibodies typically
have a concave or flat antigen binding site, VHHs have a convex
conformation with large solvent exposed CDR loops (Desmyter
et al., 1996; Muyldermans et al., 2001). The compact shape of VHHs
combined with the convex paratope allows binding into clefts or
pockets. This was demonstrated for several VHHs that inhibit enzymes like lysozyme and carbonic anhydrase (Desmyter et al.,
1996, 2001; Lauwereys et al., 1998; Transue et al., 1998; De Genst
et al., 2006; Conrath et al., 2001a, 2009). Besides this unique cavity-penetrating properties, it has also been shown that VHH can
be isolated that bind cryptic epitopes on the variant surface glycoproteins of African trypanosome, not accessible for conventional
antibodies (Stijlemans et al., 2004, 2011).
of two different VHHs recognizing overlapping or non-overlapping
epitopes on the same antigen. Besides improvements in potency,
formatting also allows the facile generation of one single molecule
capable of binding different molecules (Conrath et al., 2001b;
Harmsen et al., 2008; Hmila et al., 2010). An important multispecific application is extension of in vivo half-life of therapeutic VHHs.
Indeed the molecular weight of monovalent VHHs (15 kDa) is below the threshold of renal filtration. As a result mono, bi and trimeric VHHs are all rapidly cleared form the blood. By coupling to
an VHH that binds an abundant serum protein like albumin or
IgG, the half-life of the therapeutic Nanobody becomes similar to
that of such proteins (Harmsen et al., 2005; Roovers et al., 2007;
Tijink et al., 2008).
2.5. Alternative expression of Nanobodies
Classical antibodies are successfully expressed and secreted in
mammalian cell lines mainly. Several smaller formats derived from
conventional antibodies have been generated: monovalent antibody fragment (Fab), Fab dimer, variable fragment (Fv), singlechain Fv (scFv) and heavy or light chain single domain antibodies
(Fig. 1). Although these derivatives can be produced in other host
cells, the hydrophobic nature of the VL and VH FR2 interface remains, and is partially responsible for problems in expression yield,
solubility, stability and aggregation. In contrast, the single domain
nature of VHHs and their increased hydrophilicity enables high
production levels in microbial hosts like Escherichia coli, Pichia pastoris and Saccharomyces cerevisiae. In addition VHHs can also be
produced and function in different cellular compartments where
the formation of disulfide bonds cannot occur. VHHS have been expressed in the ER and in the cytoplasm of cells (Klooster et al.,
2009). VHHs have been successfully targeted to the nucleus or
mitochondria (Serruys et al., 2010; Van den Abbeele et al., 2010).
2.3. VHH are remarkably stable under different extreme conditions
3. Therapeutic applications
VHHs display high thermal stability. Tm values between 60 and
80 °C are the rule, not the exception with thermal unfolding often
shown to be fully reversible and functional activity sometimes retained at temperatures up to 90 °C (Lauwereys et al., 1998; van der
Linden et al., 1999; Pérez et al., 2001; Ewert et al., 2002). VHHs are
also exceptionally resistant to high pressure, chemical unfolding
with guanidinium chloride and urea, detergents or alkaline and
acid pH (Dumoulin et al., 2002; Dolk et al., 2005). Compared to
conventional antibodies and antibody-derived fragments, resistance of VHHs to proteases can be improved by in vitro selection
to generate VHHs that can resist the harsh conditions of the gastro-intestinal tract (Harmsen et al., 2006).
2.4. Enhanced functionality by easy multimerization of VHHs
The high solubility, single domain and single gene nature of
VHHs allows rapid and successful generation of multimeric VHHs
using genetically encoded amino acid linkers or carrier proteins
(Fig. 1). Bivalent, trivalent, pentavalent and even decavalent molecules have been described (Conrath et al., 2001b; Zhang et al.,
2004; Groot et al., 2006; Mai et al., 2006; Stewart et al., 2007; Stone
et al., 2007a, 2007b; Garaicoechea et al., 2008; Hmila et al., 2010).
Multimerization is an easy way to rapidly improve functional potency due to an avidity effect. Fusion of two identical anti-TNFa
Nanobodies resulted in a 500-fold increase in TNFa neutralizing
activity. The in vitro potency of this bivalent Nanobody even exceeded those of clinically used conventional antibodies (Coppieters
et al., 2006). Increased potency due to avidity has also been demonstrated for membrane bound receptors using bivalent monospecific and biparatopic VHHs (Roovers et al., 2007). The latter consists
3.1. Influenza virus Nanobodies
Influenza is an important respiratory disease caused by influenza A and B viruses. In moderate climate zones, influenza typically occurs in epidemics that peak during wintertime. Influenza
A viruses can also cause unpredictable pandemic outbreaks, associated with antigenic shift of the viral hemagglutinin. Thanks to intense global monitoring of influenza viruses, currently used
vaccines to prevent seasonal influenza have a fairly accurate antigenic composition and protect well in most target groups (Russell
et al., 2008). However, pandemic outbreaks remain unpredictable,
as illustrated by the 2009 H1N1 virus (also named Mexican flu),
which took the world and the vaccine manufactures by surprise.
In addition, outbreaks of highly pathogenic avian influenza such
as H5N1 have occurred without cessation since 2003, which has resulted in culling of more than a billion birds in the poultry industry, leading to major losses of food and economical income, mainly
in south East Asia. Occasional zoonotic infections with these H5N1
viruses and their high propensity to reassort with swine influenza
viruses, have earmarked these viruses as a major pandemic threat.
The case fatality of zoonotic infections with H5N1 viruses is close
to 60% despite intensive care interventions and the use of antiviral
drugs such as oseltamivir. In summary, there is a need for novel
treatment options against influenza. Therefore, we decided to isolate and evaluate the prophylactic and therapeutic activity of
Nanobodies directed against highly pathogenic H5N1 virus. To this
end, a llama was immunized with recombinant H5 hemagglutinin
and, following phage display and panning against the recombinant
antigen, two Nanobodies that neutralized H5N1-pseudotyped
P. Vanlandschoot et al. / Antiviral Research 92 (2011) 389–407
lentiviruses with an IC50 of 10 and 30 nM, respectively, were selected (Hultberg et al., 2011). These two Nanobodies blocked the
binding of hemagglutinin to sialic acid residues on fetuin, which
serves as an in vitro surrogate for the natural receptor. Interestingly, by producing bivalent or trivalent Nanobodies by genetic fusion of the coding information of two or three of the neutralizing
Nanobodies separated by a glycine–serine (GS) linker of variable
length the in vitro neutralizing activity against H5N1 pseudotyped
lentiviruses or against H5N1 influenza virus increased dramatically. One of the monovalent Nanobodies had an IC50 of 7 nM as
measured in a microneutralization assay against H5N1 virus,
whereas its bivalent and trivalent counterpart displayed an IC50
of 3–9 pM in the same assay (Hultberg et al., 2011). This dramatic
difference in neutralizing activity between a mono- and a bi- or trivalent VHH can partially most probably be explained by the increased avidity and by a more potent mode of interaction
involving intermolecular binding. Ultimately, however, co-crystal
structure analysis will be required to help explain the 1000-fold increase in in vitro efficacy of these Nanobodies. Remarkably, a number of H5N1 variants which were not or poorly neutralized
(IC50 > 120–150 nM) by the monovalent Nanobodies, were efficiently neutralized by the bivalent or trivalent Nanobodies
(IC50 < 10 nM).
We next assessed the in vivo efficacy of these Nanobodies in a
mouse model for H5N1 influenza (Ibañez et al., 2011). Importantly,
we decided to administer the Nanobodies intranasally. The rational
for this route of administration was in part to avoid multiple or
continuous dosing as systemic administration of Nanobodies leads
to rapid clearance from the body. Both prophylactic (up to 48 h before challenge; supporting a long local half life of Nanobodies) and
therapeutic (up to 72 h after challenge) significantly reduced virus
replication in H5-specific Nanobody treated animals. Interestingly,
also in vivo, the bivalent neutralizing Nanobody outperformed its
monovalent counterpart, by a factor 60. In addition, intranasal
administration of bivalent Nanobodies 24 h before a potentially
lethal challenge with H5N1 virus, fully protected the animals from
death and morbidity. Also in a therapeutic setting, the bivalent
Nanobodies were protective and significantly delayed time to
death. Finally, we identified the likely site of binding of the Nanobody in the HA, by selecting escape viruses in vitro. Both monoand bi-valent Nanobody selection pressure resulted in escape
viruses in which residue Lysine 189 located in antigenic site of
hemagglutinin near the receptor-binding site, was changed to glutamic acid. These findings provide proof-of-concept that Nanobodies can protect against H5N1 influenza virus challenge when
administered by the intranasal route. In addition, our results favor
the design of bi- or trivalent Nanobodies to increase their potency.
Additional experiments in another animal model such as the ferret
and the isolation of broadly neutralizing Nanobodies will be
needed to provide additional proof that the use of Nanobodies is
a highly interesting treatment option to prevent and treat influenza virus infection.
3.2. Respiratory Syncytial virus (RSV) Nanobodies
Infections by Respiratory Syncytial virus (RSV) are the leading
cause of viral acute lower respiratory tract disease in children
worldwide (Hall et al., 2009). In developed countries 1–2% of the
RSV infected infants require hospitalization. In this way RSV infections are the most important cause of infant hospitalization. Once
hospitalized, there is no effective anti-viral or anti-inflammatory
therapy available and treatment is mainly based on supplying oxygen (by mechanically assisted ventilation if required) and rehydration. As RSV infections themselves do not evoke long-living
immune protection, RSV infections repeatedly occur throughout
life, causing also significant morbidity and mortality in elderly
395
and immune compromised adults (Falsey et al., 1995; Hall,
2001). It has been estimated that annually RSV infects about 64
million people resulting in 160,000 deaths. Next to the acute consequences of infection, severe RSV infections at young age are
potentially associated with the development of long-term pulmonary distress. Despite the major clinical importance of RSV, there is
neither a vaccine nor any antiviral therapy available.
Although immune protection by natural RSV infections is partial, it correlates with high serum titers of neutralizing antibodies
and high serum titers of RSV F specific IgG antibodies (Henderson
et al., 1979). Administration of RSV neutralizing serum or antibodies was shown to reduce pulmonary RSV replication in different
animal models (Henderson et al., 1979; Taylor et al., 1984; Walsh
et al., 1984; Hemming et al., 1985; Prince et al., 1985). These findings suggested that passive immunoprophylaxis with IgG might
protect infants from RSV disease. Indeed intravenous administration of human IgG preparations enriched for RSV neutralizing antibodies could partially prevent RSV lower respiratory tract disease
in infants (Groothuis et al., 1993; Simoes et al., 1996). Hence in
1996 this therapy was approved by the FDA for the prevention of
RSV disease in high-risk infants. Subsequent palivizumab (Synagis), a humanized RSV monoclonal antibody (mAb) directed against
the conserved RSV F protein was developed. This mAb could efficiently neutralize a broad range of RSV strains in vitro (Johnson
et al., 1997). Intramuscular administration of 2.5 mg/kg palivizumab effectively reduced RSV replication in cotton rats. The impact RSV Study revealed that five monthly intramuscular injections
of 15 mg/kg could reduce RSV-related hospitalization of infants by
55%. In 1998 the FDA approved monthly intramuscular administration of palivizumab for immunoprophylaxis of RSV induced disease
in high-risk infants and children (Wu et al., 2008).
Hultberg et al. aimed at developing RSV F specific Nanobodies
with enhanced neutralizing activity (Hultberg et al., 2011). Llamas
were immunized 6 times weekly with recombinant membrane
anchorless F protein (F-TM ) derived from the RSV Long strain (subtype A) (Calder et al., 2000). Biopanning using F-TM and competitive elution using excess of palivizumab was used to enrich for RSV
neutralizing F-specific Nanobody-phages. The majority of the obtained clones were able to bind to F-TM . Twelve clones were selected for Nanobody production and purification. From these
clones two Nanobodies (RSV-D3 and RSV-C4) could neutralize
RSV A subtype Long strain virus in vitro and one clone could neutralize RSV B subtype B1 strain virus (RSV-E4). Based on competition experiments with mAbs that specifically recognize well
described antigenic sites within the RSV F protein, it was shown
that RSV-D3 and RSV-C4, bind to the antigenic site II to which also
palivizumab is binding. In contrast, the RSV-E4 Nanobody binds to
the antigenic sites IV–VI. Binding of Nanobodies to these specific
epitopes was confirmed by the use of specific RSV escape mutants.
In order to boost their neutralizing activity, monovalent Nanobodies were fused by GS linkers. Remarkably, linking two identical
RSV-D3 Nanobodies improved in vitro neutralization by about
4000-fold. As a result bivalent RSV-D3 Nanobodies (IC50:
0.11 nM) could neutralize RSV Long in vitro considerably more efficient than palivizumab (IC50: 6.5 nM). In addition bivalent RSV-D3
Nanobodies could also neutralize RSV B1 (subtype B) more efficiently than their monovalent counterparts. Linking two Nanobodies with different epitopes (RSV-D3/RSV-E4) also significantly
increased neutralization of RSV Long (subtype A, 50 to100-fold)
and RSV B1 (subtype B, 500-fold).
The neutralizing efficiency of palivizumab is about 180-fold enhanced compared to its monovalent Fab fragment. In contrast, linking of two identical monovalent RSV Nanobodies enhanced
neutralization efficiency by a much larger extend up to 4000-fold.
It is difficult to speculate on the reasons for this difference in increase of neutralization activity. Factors that could attribute to this
396
P. Vanlandschoot et al. / Antiviral Research 92 (2011) 389–407
difference might include differences in flexibility of the linkers, differences in affinity/avidity interactions, sterical hindrance caused
by the palivizumab Fc-tail, differences in size and differences in
the length of perturbing CDRs, differences in the relative ability
to bind different F proteins within the same trimer or on different
trimers (on the same or separate viruses).
3.3. Rabies virus Nanobodies
Rabies causes 55,000 human deaths per year (Knobel et al.,
2005). The virus is present in the saliva of infected animals
and transmitted by bites. From the infected wound, the virus
travels through the peripheral nerves to the central nervous system and causes lethal brain infection. Once symptoms appear,
the case-fatality rate is nearly 100%. Lives can be saved if the person receives post-exposure prophylaxis (PEP) promptly after exposure (WHO Human and animal rabies. Available from URL: http://
www.who.int/rabies/vaccines/en/mabs_final_report.pdf). Once the
first, often non-specific, symptoms occur, PEP is no longer effective.
PEP involves active immunization with vaccine and, for high-risk
exposures, immediate passive immunization treatment with antirabies antibodies. Most deaths occur in developing countries,
where people do not receive appropriate PEP, due to poor availability, high cost or simply ignorance. The antibody products available
are polyclonal IgG preparations derived from pooled plasmas of
vaccinated humans or horses (Sawyer, 2000). Since large scale production is not feasible, these are very expensive and have limited
availability. The World Health Organization urges the development
of alternatives. Cocktails of human or (humanized) mouse mAbs
are being examined as alternatives for blood-derived antibodies
(Goudsmit et al., 2006; Muhamuda et al., 2007; Müller et al.,
2009), but VHH-based Nanobodies might be another alternative.
A Nanobody (VHH) phage library was constructed from llamas
that had been immunized with inactivated Rabies Vaccine Merieux
HCDV (genotype 1, Wistar Pitman Moore Strain, Sanofi Pasteur
MSD)(Hultberg et al., 2011). Selections were performed on Elisa
strips pre-coated with Rabies G protein (Platelia II Rabies plates,
Biorad Libraries). Five Nanobodies were described that neutralized
the rabies prototype strain CVS-11 (genotype 1) virus in vitro, but
also a number of genotype 1 street isolates. IC50s for the CVS-11
strain ranged from 7 to 325 nM. Four of the Nanobodies (Rab-F8,
Rab-E8, Rab-E6 and Rab-H7) recognized overlapping epitopes in
antigenic site IIa, while the fifth (Rab-C12) recognized a totally different epitope. Despite this overlap their fine specificity was different, as only Rab-H7 and Rab-E8 could neutralize EBLV-1, a
genotype 5 strain. As was observed for RSV and H5 influenza virus
Nanobodies, improved neutralization potency could be obtained by
producing genetically fused bivalent and biparatopic Nanobodies.
For example, combining Rab-E6 with Rab-H7 resulted in an IC50
of 140 pM, which represents a 1672-fold increase when compared to the monovalent Nanobodies. Fusion of Rab-H7 to Rab-F8
resulted in an IC50 of 330 pM, which represent a 782-fold increase when compared to the monovalent counterparts. An
improvement of EBLV-1 (genotype 5) neutralization potencies
was also observed, even when one partner did not show neutralization as a monovalent Nanobody.
3.4. Poliovirus Nanobodies
Global vaccination programs that are coordinated by the World
Health Organization have not yet succeeded in eradicating poliomyelitis (Wassilak and Orenstein, 2010). Therefore, there remains
a need for developing antiviral agents against poliovirus, and such
antivirals are even simply lacking at this moment. To explore the
potential of the VHH technology as a control agent for passive prophylaxis against poliomyelitis, Thys et al. immunized a dromedary
with poliovirus type I Sabin strain (Thys et al., 2010). Following
cloning of the VHH repertoire as cDNA in a phage display vector
and panning, a total of 15 different poliovirus-binding recombinant
VHHs were selected for further characterization. These 15 VHHs
could be classified into 8 groups, based on the primary sequence
of their CDRs. Five of these VHHs, belonging to five different CDR
groups, neutralized type 1 Sabin virus (i.e. the vaccine strain used
for immunization) as well as wild type type 1 Mahoney virus. None
of the VHHs was able to neutralize type 2 or type 3 poliovirus,
which suggest a high target-specificity. Two of the poliovirus type
1 neutralizing VHHs had in vitro IC50 values of 9 and 15 nM, respectively, whereas the IC50 for the other 3 neutralizing VHHs was at
least 20-fold higher. The IC50 was defined as the concentration of
Nanobodies that inhibit the cytopathic effect of poliovirus type 1
Manhoney vrius by 50%. As a comparison, a conventional type 1
poliovirus neutralizing antibody displayed an IC50 of 8 nM in the
same assay. It is important to note here that the VHHs were used
as monovalent antiviral agents as opposed to the monoclonal IgG
antibody that is naturally bivalent. Remarkably, it was not possible
to select escape variants with two Nanobodies. The amino acid
mutations responsible for escape against the other Nanobodies
have not been reported.
The target specificity of the anti-type 1 poliovirus VHHs was diverse: the neutralizing VHHs recognized native poliovirus particle
(i.e. infectious virions), non-neutralizing VHHs bound to heat-inactivated poliovirus particles and a third set of VHHs bound to 14S
subviral particles (Thys et al., 2011). It will be interesting to study
the epitope-binding sites of the neutralizing VHHs by crystallography of the poliovirus virions in complex with the Nanobodies.
Although the world is now close to the eradication of polio because
of intensive vaccination campaigns coordinated by the World
Health Organization, the poliovirus neutralizing VHHs may still
have clinical relevance, given their ease of production and purification. However, one prerequisite for such applications will be to
demonstrate efficacy against poliomyelitis in an animal model.
3.5. Foot-and-mouth disease virus (FMDV) Nanobodies
Another Picornavirus against which neutralizing Nanobodies
have been generated and characterized is foot-and-mouth disease
virus (FMDV). FMDV is harmless to man, but this highly contagious
virus can cause devastating disease and mortality in cloven-hoofed
livestock. Because European authorities impose a non-vaccination
policy against FMDV, livestock in this continent are particularly
susceptible to this virus. Measures to control outbreaks include a
ban of animal transport, rapid vaccination of animals in affected regions and culling of affected herds. An effective passive immunotherapy with FMDV neutralizing antibodies (e.g. hyperimmune
serum) could also be implemented because it would provide more
rapid protection and presumably reduce virus transmission earlier
compared to vaccination. However, there are some hurdles to overcome to envision such an approach. The therapy should be economical, implying that therapy with FMDV-neutralizing mAbs or
convalescent serum would be far too expensive to use in the field.
In addition, there are at least 7 serotypes of FMDV and hence a
broadly neutralizing serum would be required. Finally, protection
against unique antigenic sites is associated with a high risk for escape virus selection, making a mono-selective antiserum
ineffective.
Harmsen et al., tried to circumvent some of these consideration
by using Nanobodies (Harmsen et al., 2007). These researchers
immunized llamas with a mixture of 4 strains of serotype O FMDV,
to select high affinity VHH clones by phage display. Interestingly,
the authors expressed the candidate FMDV-inhibiting VHHs – 21
unique neutralizing VHHs were isolated – as secreted recombinant
Nanobodies in S. cerevisiae. A mixture of two different VHHs dis-
P. Vanlandschoot et al. / Antiviral Research 92 (2011) 389–407
playing synergistic in vitro FMDV-neutralizing activity turned out
to be most effective in a passive prophylaxis setting. However, protection was only partial whereas a convalescent guinea pig serum
with a comparable in vitro neutralizing titer fully protected the animals against the development of FMDV lesions. Since the Nanobodies had been PEGylated to increase their serum half life, the
limited in vivo protection was presumably due to the lack of Fcdependent antiviral effector mechanisms, such as opsonophagocytosis, i.e. binding of antibodies to virions followed by phagocytosis
of the opsonized virions by macrophages.
In a follow-up study using a swine model for immuno-prophylactic treatment against FMDV challenge, bispecific Nanobodies
were engineered (Harmsen et al., 2005, 2008). These bispecific
Nanobodies combined one of three VHHs that neutralized FMDV
in vitro with a second VHH that binds with high affinity to porcine
Immunoglobulin G light chain (Harmsen et al., 2005). The rational
for this approach was to increase the serum half-life of the Nanobodies, as an alternative for PEGylation. Addionally it was assumed
that this VHH would not interfere with Fc-encoded effector functions. Both VHHs, i.e. the FMDV neutralizing and the Ig-binding
VHHs were separated by a short GGS linker and produced in
S. cerevisiae in a 100 L fermentor before affinity purification based
on a C-terminal poly-histidine tag. The affinity and in vitro FMDV
neutralizing activity of the bispecific VHHs was comparable with
their respective monovalent counterparts with KD values as low
as 0.3–0.5 nM. Likewise the affinities of the bispecific VHHs for
swine Ig was comparable to that of the monovalent swine Igbinding Nanobody (KD approximately 1 nM). However, when the
bispecific VHHs were complexed with pig Ig, the in vitro neutralizing activity of two out of tree VHHs increased 4- to 30-fold, presumably as a result of steric hindrance and/or avidity effects.
Intramuscular administration of a dose of 3 mg/kg in pigs 24 h prior
to challenge with 1000 plaque-forming units FMDV resulted in reduced viremia and virus shedding but did not prevent transmission.
To further increase the neutralizing activity of the anti-FMDV
Nanobodies, bispecific VHHs were constructed with two VHH domains directed against the virus and a third VHH directed against
swine Ig (Harmsen et al., 2009a,b). This resulted in VHHs with a 5fold higher neutralizing activity. These molecules, again produced
in S. cerevisae, were able to reduce clinical disease, viraemia, virus
shedding and now also transmission in a pig model when administered (i.v. in the ear) at a dose of 50 mg/kg, 24 h before intradermal inoculation with 10,000 TCID50 of FMDV. Finally, the authors
also demonstrated that the presence of FMDV-neutralizing VHHs
did not interfere with the immune response upon vaccination with
conventional FMDV vaccine. This is an important finding because
FMDV vaccination of animals that are at risk for being infected is
used to try to control outbreaks. In summary, this development
of FMDV-neutralizing Nanobodies has provided proof-of-concept
that passive immuno-prophylaxis can protect animals against
FMDV-induced disease. In particular engineering steps to produce
trivalent Nanobodies in which two of the three paratopes have
in vitro FMDV neutralizing activity and the third paratope allows
high affinity binding to circulating immunoglobulin, proved to be
effective in preventing disease and transmission. However, it remains to be determined if FMDV-escape viruses would be rapidly
selected upon use of such a Nanobody-based intervention, and if
a similar approach would also be effective against the other FMDV
serotypes.
3.6. Rotavirus Nanobodies
Group A Rotavirus (RV) strains are the most frequent cause of
acute gastroenteritis in infants and children under the age of 5.
Although fatal outcome of RV infections in developed countries
are rare, RV infections cause annually more than 500,000 deaths
397
worldwide (Parashar et al., 2006). RV is a non-enveloped double
stranded RNA virus with an outer and inner capsid. The outer capsid is composed of VP4 and VP7 proteins, which are highly variable.
Based on the variability of VP7 and VP4, Rotaviruses diverge into
23 G (based on the VP7 glycoprotein) and 31 P (based on the protease-sensitive VP4 protein) serotypes. RV infections induce neutralizing antibodies specific for VP4 and VP7 (Ward, 2009). Upon
primary infection these neutralizing antibodies are mainly serotype specific and can hence protect against homosubtypic infections. The inner capsid is composed of VP6 proteins which are
immunodominant and highly conserved. Although VP6 antibodies
can protect mice from RV infection VP6 antibodies do not neutralize RV in vitro (Burns et al., 1996). Their protective capacity can
however be explained by polymeric VP6 IgA antibodies that neutralize RV via transcytosis (Corthésy et al., 2006).
Rotarix and Rotateq are two licensed vaccines that have been
shown to protect against the main circulating RV strains (G1, G2,
G3, G4 and P1A) and are hence applied in childhood vaccination
programs. Next to vaccines, oral administration of antibodies
against VP7 and VP4 has also been shown to prevent or treat RV
infections in children (Sarker et al., 2001). As a more feasible alternative to preparations of conventional antibodies, van der Vaart
et al. developed RV neutralizing Nanobodies that are produced in
yeast (van der Vaart et al., 2006). A Nanobody (VHH) phage library
was constructed from circulating plasma cells derived from a llama
that had been immunized five times with whole Rhesus rotavirus
(RRV, G3 serotypes). RV binding phages were selected by biopanning, using the RRV strain that was used for immunization. As orally administered anti-RV Nanobodies should be functional in the
gut they must resist the acidic conditions of the stomach. Therefore, as part of the selection strategy, the phages were pre-treated
at low pH (pH 2.3). The selected Nanobodies were screened and
further selected for binding to RRV and a second G3 serotype RV
(CK5). Neutralizing Nanobodies and control Nanobodies were recloned for production in S. cerevisiae. The yeast produced Nanobodies were tested for CK5 RV in vitro neutralization. The most potent
Nanobody (2B10) could neutralize CK5 RV in an in vitro plaque assay with an IC50 of approximately 3 nM. Neutralizing Nanobodies
that could be efficiently produced in yeast were also tested in a
mouse pup model for rotavirus infection. Daily oral administration
of 50 or 100 lg 2B10 Nanobody could either prevent diarrhea or
reduce the number of days with diarrhea per pup. These findings
illustrate that oral administration of yeast produced Nanobodies
could be a feasible strategy for reducing rotavirus induced acute
gastroenteritis in infants (van der Linden et al., 1999; van der Vaart
et al., 2006). Immunization, selection and in vivo testing of the described Nanobodies were all performed with whole G3 serotype
rotaviruses. Therefore it is unclear whether the described antirotavirus Nanobodies are also effective against other circulating
human rotavirus serotypes. As for conventional antibodies, only
VP7 or VP4 specific antibodies can neutralize rotavirus in vitro,
one could conclude that also the neutralizing rotavirus Nanobodies
are directed against either VP7 or VP4 and would therefore be specific for G3 serotype rotaviruses. However, as Nanobodies differ
considerably from conventional antibodies, the neutralizing Nanobodies might access more conserved neutralizing epitopes within
the VP7 of VP4 proteins or within other more conserved rotavirus
proteins such as the immune dominant VP6 protein (see later) (De
Genst et al., 2006). In the absence of a defined epitope of these
Nanobodies it is difficult to speculate on the mechanism by which
they neutralize rotavirus. As the described Nanobodies are monovalent it is unlikely that these Nanobodies neutralize rotavirus by
cross linking multiple infective viral particles. These findings illustrate that Nanobodies have the potential to be investigated as an
oral prophylactic treatment against rotavirus induced gastroenteritis in infants.
398
P. Vanlandschoot et al. / Antiviral Research 92 (2011) 389–407
As mentioned before the rotavirus inner capsid protein VP6 is
highly conserved and highly immunogenic but is not or rarely a
target for neutralizing conventional antibodies (Burns et al.,
1996; Corthésy et al., 2006). Garaicoechea et al. investigated if this
VP6 protein might be a target for neutralizing Nanobodies (Garaicoechea et al., 2008). A llama was immunized 5 times with Sf9 cell
extract containing recombinant VP6 protein, derived from the Bovine rotavirus C486 strain. After the final immunization a high
amount of rotavirus specific antibody-secreting cells were detected
in the blood. In contrast, as expected there was no increase in virus
neutralizing antibody titer. From the circulating mononuclear cells
a Nanobody phage display library was constructed. RV binding
phages were enriched by successive biopanning, using a bovine
rotavirus strain (BRV IND). Phage clones with strong specific binding to rotavirus and recombinant VP6 were recloned into a Nanobody expression vector for production in E. coli. After purification
four selected Nanobodies were all shown to recognize a series of
rotaviruses from human and animal origin with different VP6 specificities and different G and P serotypes. Three of the four tested
Nanobodies could also neutralize these rotaviruses in vitro (IC80
ranging from 13 to 1000 nM). Remarkably homo-bivalent formats
of these Nanobodies could neutralize these rotaviruses less efficiently. These findings suggest that in contrast to large conventional antibodies of Fab fragments, small monovalent Nanobodies
can efficiently access conserved neutralizing epitopes within the
inner capsid VP6 protein. As VP6 has been shown to be involved
in viral entry via interactions with hsp70 cellular protein, Nanobodies might prevent infection by interfering with the binding between VP6 and hsp70 (Gualtero et al., 2007). The protective
potential of these Nanobodies was investigated in a mouse pup
model for rotavirus induced diarrhea. Daily, a single dose of
100 lg of monovalent Nanobody was administered intragastrically. On the second day the pups were challenged with either bovine
or mouse rotaviruses. Treatment with Nanobody 3B2 could significantly reduce the prevalence of bovine and murine rotavirus induced diarrhea. These findings suggest that VP6 specific
Nanobodies could potentially protect against most circulating rotavirus strains. This study has demonstrated that Nanobodies, likely
due to their small size and long CDR3, can reach neutralizing epitopes that are inaccessible for conventional antibodies or Fab
fragments.
As especially infants from developing countries would benefit
from Nanobody based anti-rotavirus therapy, such a therapy
should be inexpensive and very easy to distribute, store and apply.
To overcome these hurdles Pant et al. investigated the possibility of
an anti-rotavirus therapy based on Nanobody expressing lactobacilli, which are normal commensals of the gut (Pant et al., 2006).
Recombinant Lactobacilli paracasei expressing either surface membrane-anchored (Nanobody fused to the long anchor sequence of
the L. casei proteinase P gene) or secreted anti-rotavirus 2B10
Nanobody were constructed. When mixed with recombinant lactobacilli, multiple rotaviruses bound to lactobacilli that express
membrane anchored Nanobody. Both secreted Nanobodies and lactobacilli (starting from 1000 CFU) that express membrane anchored Nanobody could neutralize G3 serotype rotavirus (RRV)
in vitro. After oral treatment of mice with Nanobody-anchored lactobacilli, Nanobody expressing lactobacilli could be detected in the
murine intestine. It is not clear whether the detected Nanobodies
on the surface of lactobacilli in the gut, represent Nanobodies that
resisted the environment of the stomach and gut or represent newly synthesized Nanobodies. By surviving these conditions and
allowing de novo Nanobody expression, lactobacillus might act
as stealth for Nanobody delivery to hard to reach sites. Daily
administration of Nanobody-anchored lactobacilli (1.108 cfu),
starting from 1 day before rotavirus challenge (20 diarrhea doses50
RRV) could reduce the rotavirus titer in the small intestine, the
prevalence, duration and severity of diarrhea and inflammation
of the small intestine in mouse pups. Comparable protection was
also observed for reconstituted lyophilized Nanobody-anchored
lactobacilli. Importantly, recombinant lactobacilli in which the
coding sequence of the membrane-anchored Nanobody was integrated in its chromosome were able to reduce the duration and
severity of rotavirus induced diarrhea to comparable extend as lactobacilli that express this Nanobody from plasmids (Martín et al.,
2011). In contrast, lactobacilli expressing secreted Nanobodies
did not protect against rotavirus induced diarrhea (Pant et al.,
2006). This is in line with the observation that monovalent Nanobodies that neutralize rotavirus infection in vitro do only reduce
rotavirus induced diarrhea in mice when administered in high
doses (>10 lg). The authors suggest that the protective activity of
Nanobodies anchored to the lactobacillus surface membrane is
due to the multivalency of these anchored Nanobodies that allow
high avidity interactions. In addition lactobacilli might contribute
to protection by killing bound viruses via the production of antiviral molecules such as lactate. Although in this study it was indicated that the described Nanobodies could react with a variety of
human strains is was not reported whether they could also neutralize and protect against other human rotavirus serotypes. Ideally, to be protective against most circulating rotavirus strains,
lactobacilli should express either a mix of Nanobodies with different specificities at their surface or a single Nanobody that is specific for a strongly conserved neutralizing epitope. This study has
illustrated that polypeptide Nanobodies are suitable to be delivered by commensal micro-organisms like lactobacilli.
3.7. Human Immunodeficiency virus (HIV) Nanobodies
Since the start of the HIV pandemic in 1981 over 25 million people have died from acquired immunodeficiency syndrome (AIDS).
Current therapy effectively suppresses viral replication, but cannot
eradicate the virus and as such does not cure the disease. The therapy has considerable side-effects, is very expensive, lifelong treatment is needed and drug resistance can develop. Approved
antiretroviral drugs can be broadly classified by the phase of the
retrovirus life-cycle that the drug inhibits and have focused on 5
viral and 1 cellular proteins: reverse-transcriptase, integrase, protease, gp41, GAG and CCR5. Effective preventive methods are another way to control the pandemic. However, the developments
of topological microbicides and vaccines, that prevent viral entry
and thus could prevent transmission, have proven difficult. HIV entry into target cells is mediated by the trimeric viral envelope protein which consists of gp120 non-covalently bound to the
membrane bound gp41 unit (Dalgleish et al., 1984; Klatzmann
et al., 1984; Wyatt and Sodroski, 1998). The gp120 binds first
CD4 on the target cell and following a conformational change
gp120 binds either CCR5 or CXCR4 (Moore et al., 1997). This interaction is normally followed by a gp41-induced fusion of viral and
plasma membrane. A very small number of mAbs have been isolated that display broad-neutralizing activity (Binley et al., 2004).
Two mAbs, called b12 and 2G12 are directed against gp120. Mab
b12 binds an epitope that overlaps a subset of the CD4-binding
site, while mAb 2G12 recognizes a carbohydrate motif (Burton
et al., 1991, 1994; Barbas et al., 1992; Roben et al., 1994; Zhou
et al., 2007). Mabs 4E10 and 2F5 bind gp41 (Buchacher et al.,
1994; Trkola et al., 1996; Sanders et al., 2002), while mAb X5 binds
to a gp120 epitope exposed after binding to CD4 (Moulard et al.,
2002). These antibodies are from individuals infected with HIV-1
subtype B, the dominant subtype in North-America and Europe.
So far, immunizations of animals and humans with recombinant
gp120 or gp140 have not resulted in successful induction of
broadly-neutralizing antibodies and isolation of broadly neutralizing mAbs. Because of the small size of VHH, combined with their
P. Vanlandschoot et al. / Antiviral Research 92 (2011) 389–407
protruding CDR3 loops and their cleft-recognition properties, it
was hypothesized that VHH might be able to recognize conserved
epitopes.
3.7.1. HIV gp120 Nanobodies
Forsman et al. immunized llamas with recombinant gp120 derived from a subtype B/C virus (CN54) (Forsman et al., 2008). To increase the chance of isolating broad-neutralizing Nanobodies,
panning was followed by competitive elution with soluble CD4.
Panning on the CN54 gp120 yielded one Nanobody out of 96
tested, that did bind recombinant CN54 gp120 protein. Although
this Nanobody neutralized the CN54 virus, it did not neutralize
other HIV strains. In a second attempt, recombinant gp120 from
another clade B strain (IIIB) was used in the selection effort. This
time, 30 clones out of 48 tested were shown to bind IIIB gp120
and 24 of these did neutralize the IIIB virus. From this effort, three
Nanobodies (A12, D7 and C8) that were able to neutralize a limited
panel of subtype B and C isolates were selected. In a third and final
attempt, alternating selections against recombinant gp120 from a
subtype A, a subtype C virus and IIIB were performed. Out of 700
clones tested, only 43 did bind gp120 and did neutralize HIV. However, these 43 clones were shown to be identical to the A12 clone
isolated already in the second attempt. Further characterization
demonstrated that A12 neutralized 42% of the strains tested with
IC50s in the range of <0.2–2533 nM. Nanobody D7 neutralized
31% of the virus panel and Nanobody C8 neutralized 35% of the
strains. A12 and D7 seemed more potent against subtype B viruses.
In comparison, the well known mAb b12 neutralized 54% of the
viruses. The three VHH, like mAb b12 did not neutralize strains
that belong to clade A, A/G or D. The Nanobodies did bind with
affinities between 0.1 and 1 nM to gp120 and blocked binding of
CD4 to gp120. The Nanobodies also competed with binding of
mAbs known to bind to the CD4 binding site of gp120. Finally it
was demonstrated that CD4 inhibited binding of the Nanobodies
to gp120 and that the Nanobodies competed with each other for
binding to gp120 (Forsman et al., 2008).
The structure of D7 resembles known llama VHH structures,
contains two canonical CDR1 and CDR2 conformations and a long
18 residue CDR3 with a non-canonical conformation (Hinz et al.,
2010). The structure revealed that the tip of the long CDR3 is highly
mobile and suggest that this conformational flexibility might be
important for gp120 recognition. A comparison with the CDR3
loops of antibodies that bind to CD4 site on gp120 did not reveal
any significant structural homology, indicating differences in binding mode. Mutational analysis identified 3 CDR3 residues that
make crucial contributions to the interaction with IIIB gp120.
One of these key residues is part of the flexible tip, further emphasizing the importance of the CDR3 flexibility in binding IIIB gp120.
The same mutations that lead to this decreased interactions with
IIIB gp120, resulted in weaker neutralization potencies. Comparison of the D7 and A12 sequence demonstrated differences in
CDR1, CDR2 and CDR3, which could account for the higher neutralization potency of A12. Indeed, introduction of the A12 CDR3
residues YYD into D7, resulted in a 10-fold improved affinity and
5-fold improved neutralization.
In a follow up study, Koh et al. reported a new approach to isolate Nanobodies closely related to A12 and D7 (Koh et al., 2010).
They constructed an A12/D7 family specific phage display library,
using a degenerate primer that recognizes the C-terminal stretch
of nucleotides in the CDR3 loops and the first 4 conserved amino
acids of framework 4 of A12/D7. Together with a primer to a highly
conserved frame work 1 region RNA was amplified by PCR and a
phage display library constructed. From this library 49 unique
VHH amino acid sequences were isolated with high homology to
A12 and D7. Variations in the frame work regions as well as in
the CDRs were observed. Of these, 15 were tested and shown to in-
399
hibit binding of sCD4 to gp120. Thirty-one clones, including the 15
tested for CD4 inhibition, were evaluated in HIV neutralization assays against 3 subtype B and 3 subtype C viruses. While all Nanobodies showed identical neutralization profiles against the B
strains, three different neutralization profiles (Broad A12-like,
Intermediate and Narrow D7-like potency) could be distinguished
for the C type strains. To understand the underlying molecular basis of these differences, the amino acid sequences of the CDRs were
studied. Interestingly, a triple amino acid motif YYD at the C-terminal end of the CDR3 was suggested to be crucial for the broad neutralizing potency of A12/D7 family members. Mutations in this
triple motif changed the neutralization phenotype from Broad to
Narrow and vice versa, demonstrating that this YYD motif is indeed
responsible for the broad potency against subtype C viruses. Finally, it was demonstrated that Nanobodies with affinities <1 nM for
IIIB gp120 all carried the YYD motif. All Nanobodies with affinities
>1 nM were without this motif.
Overall this work on the anti-gp120 Nanobodies has demonstrated for the first time that broadly neutralizing antibodies can
be obtained upon immunization. It also suggests that such Nanobodies can be considered for applications as microbicide development. In addition this work demonstrates that Nanobodies might
be very useful tools to define broadly-neutralizing epitopes in order to rationally design HIV-1 vaccines.
3.7.2. HIV Rev Nanobodies
HIV RNAs are exported from the nucleus to the cytoplasm (Pollard and Malim, 1998). Cellular mechanisms export fully spliced
viral mRNA, but to transport unspliced viral RNAs, the Rev protein
is essential and exploits the CRM1-mediated cellular machinery
(Fornerod et al., 1997; Fukuda et al., 1997; Neville et al., 1997).
The Rev protein recognizes the Rev responsive element (RRE, a secondary structured RNA element) present in the (partially) unspliced viral mRNAs. Rev consists of 116 amino acids. A stretch of
10 arginine residues serves both as a nuclear localization signal
(NLS) and an RNA binding domain. This basic stretch is flanked
on both sides by sequences that contribute to Rev oligomerization
on the RRE (Malim et al., 1989). A leucine-rich nuclear export signal (NES) binds CRM1 and mediates nuclear export (Fischer et al.,
1995) (Daelemans et al., 2005). The essential role of Rev in HIV replication makes this protein an important therapeutic target. Candidate Rev inhibitors all target the Rev-RRE or the Rev-CRM1
interaction. Rev multimerization, which is crucial for efficient viral
replication, has not been targeted. Rev specific Nanobodies were
isolated from llamas immunized with recombinant Rev (Vercruysse et al., 2010, 2011). After 3 rounds of selection on immobilized Rev protein, 12 different Nanobodies that interacted with Rev
protein were selected. An in vitro multimerization assay based on
fluorescence resonance energy transfer (FRET) was designed to
identify Nanobodies that inhibit Rev multimerization. Only one
Nanobody, Nb190 was shown to inhibit the Rev protein–protein
interaction. This Nanobody not only inhibited multimerization of
Rev but it could also disassemble existing multimers of Rev, confirming the dynamic nature of the Rev-Rev interaction. Nb190
complexed with Rev still interacted with the RRE, but prevented
further Rev assembly on the RRE, causing an accumulation of Rev
dimers on the RNA. Rev residues critical for the interactions with
Nb190 were shown to be Lys20 and Tyr23 in the N-terminal alpha-helix. To study whether inhibition of Rev multimerization
could also interfere with Rev-mediated functions, Nb190 was expressed as an intrabody in mammalian cells. Expression of Rev in
HeLa cells localized primarily to the nucleoli while Nb190 was
found in cytoplasm and nucleus. Upon co-expression of Rev and
Nb190, both proteins co-localized in the cytoplasm. Using inhibitors of nuclear export and disruption of the NES, it was demonstrated that Nb190 does not prohibit shuffling of Rev between
400
P. Vanlandschoot et al. / Antiviral Research 92 (2011) 389–407
nucleus and cytoplasm. It was further demonstrated that Nb190
inhibits Rev protein–protein interactions and inhibited the Rev
dependent expression of a RRE reporter system. Finally, it was
demonstrated that cytoplasmic expression of Nb190 dose-dependent inhibited HIV production. Moreover, it was demonstrated that
in the presence Nb190 the late viral unspliced and partially RNA
species were no longer detectable. Overall this data demonstrated
that Nb190 is the first molecule that prevents the formation of a
large protein complex required for HIV mRNA export to the cytoplasm. It also demonstrates that interfering with Rev multimerization is a valid approach to inhibit HIV replication.
3.7.3. HIV Nef Nanobodies
The Nef protein is a multifunctional non-structural HIV protein.
Nef is necessary for full HIV-1 virulence and has been defined as a
pathogenic factor because disease progression is lacking in patients
infected with Nef deleted viruses. Whether Nef is directly pathogenic remains to be dissolved (Foster and Garcia, 2008). Nef is a
small myristoylated protein of 200–215 amino acids. It is found
in the cytoplasm, mainly localized in the paranuclear region. Four
in vitro Nef activities have been documented and each of these
could contribute to the Nef-induced pathologies: down regulation
of CD4, down regulation of MHC-I molecules, cellular signaling and
activation and infectivity enhancement of viral particles by
CD4-independent mechanism. Different motifs located in different
locations of Nef are involved in the different Nef-mediated actions.
Given its central role, targeting Nef might prevent or delay pathogenesis, yet only a few Nef-inhibitors have been described
(reviewed in Foster and Garcia, 2008). A Nef Nanobody, sdAb19,
was isolated from a llama immunized with a recombinant Nef fragment (aa 57–205) (Bouchet et al., 2011). It was identified in an
ELISA on immobilized Nef and has a calculated KD of 2 nM as determined by surface plasmon resonance. A cytoplasmic and nuclear
distribution was observed upon expression of sdAb19 in cells.
Upon expression of sdAb19 in Nef-GFP producing cells, both proteins co-localized in cytoplasmic dotted structures, concentrated
in the perinuclear region. Co-localized association was confirmed
by immune precipitation experiments. sdAb19 did not bind a Nterminal deletion mutant (aa1–61), core deletion mutant (aa 58–
189) and C-terminal deletion mutant (aa 160–206). This suggests
that this Nanobody recognizes a conformational core domain
structure. sdAb19 was able to cross-react with a broad panel of
Nef proteins derived from different HIV-1 groups. Upon co-expression of Nef and sdAb19, the Nef-induced down regulation of CD4
was dose-dependently inhibited. This probably resulted from inhibition of the Nef-mediated CD4 internalization likely through
interference with AP complex machinery. The Nanobody failed to
inhibit Nef-induced down regulation of MHC-I cell surface expression. Expression of sdAb19 reversed the inhibitory effect of Nef on
anti-CD3 induced actin remodeling in T cells, probably by inhibition of Pak2 and subsequently cofilin phosphorylation. When
sdAb19 was expressed during production of GFP reporter viruses,
the Nanobody was incorporated into the viral particles. The incorporation was Nef dependent. This presence of the Nanobody reduced viral infectivity of GFP reporter viruses capable of a single
round infection only. A similar reduction in viral infectivity was observed when replication competent viruses were produced first in
the presence of sdAb19. Finally, it was demonstrated that sdAb19
inhibited Nef-mediated activities in vivo, using transgenic mice in
which expression of the Nef gene is driven by the CD4 regulatory
sequences. In these mice Nef is expressed in CD4 T cells and cells
of the monocyte/macrophage lineage (Hanna et al., 1998). In such
animals, CD4 cell surface down regulation, altered thymic CD4 T
cell development and peripheral CD4 T cell depletion has been
demonstrated. Transplantation of such mice with Nef transgenic
fetal liver cells, first infected with a retrovirus encoding the sdAb19
Nanobody, demonstrated reversal of the thymic maturation defect.
Moreover there was also a reversal of the CD4 down regulation in
these thymic CD4 T cells. This reversal was not due to absence of
Nef. sdAb19 also reduced the number of activated (effector/memory) peripheral CD4 T cells, but did not prevent their depletion.
Overall this data demonstrate that Nanobodies against Nef are
excellent tools to study the role of Nef in viral replication and disease progression. The work also demonstrates that it is possible to
interfere with important functions of Nef with a single agent.
3.7.4. CXCR4 Nanobodies
Until recently, approved antiviral drugs were always directed
against viral proteins. Maravoric, which was approved in 2007, is
probably the first anti-viral drug that targets a cellular protein.
Maravoric binds CCR5, preventing the interaction of HIV gp120
with this co-receptor for viral entry. Besides CCR5, HIV can also
use CXCR4 as a co-receptor for viral entry (Moore et al., 1997).
Viruses using CXCR4 are typically associated with development
of AIDS. AMD3100, a CXCR4 antagonist, which is now approved
for stem cell mobilization, was originally developed for blocking
HIV entry. The chemokine receptors CCR5 and CXCR4 are members
of the large family of G protein coupled receptors (GPCRs). These
represent the largest family of drug target proteins to date and
they are mostly targeted by small molecules. GPCRs appear to be
difficult targets for antibody-based therapeutics. To investigate
the potential of Nanobodies to target GPCRs, Jähnichen et al., selected CXCR4. Llamas were immunized with HEK293T cells transiently transfected with human CXCR4 (Jähnichen et al., 2010). In
the first round of phage selections cell membranes of CHO cells,
over-expressing CXCR4 were used. Counter selection with nontransfected CHO cell membranes was performed to deplete nonCXCR4 specific phages. In a second round of selection, membranes
from CXCR4-expressing COS-7 cells were used. A total of only 180
Nanobodies were selected and periplasmatic fractions were
screened for competition of the natural CXCR4 ligand SDF-1
(CXCL12). Two Nanobodies, 238D2 and 238D4, were shown to inhibit bind of radiolabeled SDF-1 to CXCR4. Following sequencing
and purification of these Nanobodies, the binding characteristics
were determined. Both Nanobodies fully displaced binding of
SDF-1 showing potencies in the low nM range. Both Nanobodies
specifically competed each other for binding to CXCR4. AMD3100
displaced binding of 238D2 and 238D4. A well known mAb 12G5
also inhibited binding of the Nanobodies to CXCR4. Using a shotgun mutagenesis approach the epitope of 238D2 and 238D4 was
mapped (Jähnichen et al., 2010). Both Nanobodies focus on the second extracellular loop, but different amino acids are involved. Critical residues for binding of 238D4 are D187, F189, E179 and S178.
Critical residues for binding of 238D2 are F189, N192, W195, P191,
V196 and also E277, a residue located in the third extracellular
loop of CXCR4. Importantly, F189 appears critical for binding of
both Nanobodies. 238D2 and 238D4 are highly selective for human
CXCR4, as no binding to mouse CXCR4 was detected. In addition,
the Nanobodies did not bind or alter the agonist-induced activity
of 11 other GPCRs tested. 238D2 and 238D4 were shown to inhibit
SDF-1 induced signaling and SDF-1 induced cellular chemotaxis of
Jurkat leukemia T cells. Astonishingly, two biparatopic Nanobodies,
obtained by short peptide linkage of 238D2 to 238D4, resulted in a
significantly increased affinity for CXCR4. SDF-1 displacement and
inhibition of chemotaxis now reached picomolar potencies. Interestingly, only these biparatopic Nanobodies were capable of reducing the high basal signaling activity of a constitutive active CXCR4
mutant. The monovalent 238D2 and 238D4 Nanobodies were finally shown to display anti-HIV-1 activity. Nanomolar (10–100 nM
IC50) inhibition was observed against the CXCR4-using lab strain
(NL4.3) but also for the HE strain which can use both CXCR4 and
CCR5. Viral infection mediated by CCR5 using the BAL strain was
P. Vanlandschoot et al. / Antiviral Research 92 (2011) 389–407
not inhibited, again demonstrating the high selectivity of 238D2
and 238D4 for CXCR4. The anti-HIV activity of the Nanobodies
was independent of the types of cells (cell lines or PBMC). When
the biparatopic 238D2–238D4 Nanobodies were tested again a significantly increased inhibitory potency was obtained. The IC50 for
the CXCR4-specifc NL4.3 virus reached 100–250 pM. A more potent inhibition (2 nM IC50) was also observed for the HE strain,
while infection of the BAL strain was still not affected. In conclusion, in this study the isolation and rapid generation of the most
potent CXCR4 antagonist and HIV entry blockers were reported.
3.8. Hepatitis B virus (HBV) Nanobodies
3.8.1. HBV S domain Nanobodies
Hepatitis B virus infections represent a global health problem.
With 400 million people infected and 500,000–700,000 deaths
per year, the virus can be considered a destructive major health
burden (Lavanchy, 2008). Effective prophylactic vaccines are available, but therapy with interferons and synthetic nucleos(t)ide reverse transcriptase inhibitors are the only approved treatments.
Interferons are only effective in 20–40% of patients and cause
numerous side effects. Appearance of drug resistant mutants is a
recurrent problem with the reverse transcriptase blockers
(Hilleman, 2003; Lavanchy, 2005). A number of novel strategies
to combat chronic HBV infections are being explored. One approach is the use of intrabodies. Using Nanobodies, Serruys et al.
demonstrated for the first time intrabody-mediated inhibition of
viral replication in vivo (Serruys et al., 2009). A late step in the
HBV replication cycles, namely secretion of viral particles (virions
and non-infectious viral like particles), was targeted. Nanobodies
used recognized the HBV S domain (HBsAg) present in the three
viral membrane proteins (S, M and L) (Serruys et al., 2009). These
three proteins all share 226 C-terminal amino acids S domain.
The M and L proteins have N-terminal amino acid extensions.
The S protein is the most abundant viral membrane protein. Llamas
were immunized with serum derived non-infectious viral-like particles. These contain S, M and L proteins. To isolate S domain specific Nanobodies, panning was performed on recombinant VLPs
that only contained S protein. Five Nanobodies were selected that
were shown to bind S protein with different affinities. To express
these Nanobodies in eukaryotic cells, their coding sequence was
cloned into an expression vector in frame with an ER-targeting sequence and the SEKDEL ER-retention signal. Co-transfection of the
HepG2 hepatoma cell line with these plasmids together with an
HBV-expressing plasmid was performed to study the effect on
secretion of viral particles. Confocal microscopy revealed the presence of Nanobodies in the ER, co-localizing with the S domains.
Interestingly, more positive cells with a more intense S domain
staining were observed, only when S-specific Nanobodies were
co-expressed. This suggested a Nanobody-mediated intracellular
accumulation of the S domains. Indeed, the levels in cell supernatant of secreted S domains dropped by more than 80–90%, while
there was an accumulation detected inside the cells. There was a
selective retention of the S domains, because the secretion of another HBV protein (HBeAg) was not affected. Whether the S domain specific Nanobodies can reduce secretion of HBV viral
particles in vivo was tested in the hydrodynamics-based HBV
mouse model (Yang et al., 2002). The Nanobody and HBV expressing plasmids were co-injected intravenously in immune deficient
Scid mice (Serruys et al., 2009). Immunohistochemistry demonstrated expression of the five different Nanobodies in hepatocytes
at day 1 after injection of the plasmids. By day 7 very little Nanobody was detected. The presence of the HBV nucleocapsid protein
was clearly detected from day 1 to day 7. However, only at day 4
after plasmid injections, the intracellular presence of the S proteins
in hepatocytes was observed. Importantly, this was only observed
401
when an S domain specific Nanobody was expressed. This suggested that the S domain specific Nanobodies prevented secretion
of S molecules and were capable of retaining S molecules inside the
hepatocytes. Indeed, the concentration of the VLPs and more
importantly HBV virions in the blood were reduced significantly
(10- to >100-fold). In addition an increased amount of intracellular
S proteins was demonstrated further confirming the intracellular
retention of viral envelope proteins. The secretion of another
HBV protein (HBeAg) was not affected, demonstrating that the S
domain specific Nanobodies had no inhibitory effect on protein
secretion in general. No evidence for Nanobody induced liver damage (hepatocyte apoptosis and kuppfer cell activation) was observed. Overall, these reports provided proof of principle for the
use of Nanobody-based intrabodies to inhibit viral replication by
interference with viral secretion in vivo.
3.8.2. HBV nucleocapsid Nanobodies
HBV nucleocapsids are formed in the cytoplasm by 180–240
monomeric core proteins. During this multimerization process
one copy of viral pre-genomic RNA (pgRNA) is encapsidated (Bruss,
2007). Nucleocapsids can either move to the ER where they interact with the cytoplasmic loops of the viral membrane proteins.
This leads to budding of virions into the secretion pathway. The
cytoplasmic nucleocapsids can also be transported to the nucleus,
where they disintegrate and release the viral genome (Rabe et al.,
2003; Kann et al., 2007). This causes persistence of viral infection
of the cells. The biological role of the nucleocapsids in the nucleus
is unclear, although it has been suggested they function as interferon antagonists. The HBV nucleocapsid is an attractive new therapeutic candidate, and several small molecule antivirals have
shown to inhibit viral replication (Feld et al., 2003; Xu et al.,
2003; Zoulim, 2011). Nanobodies binding the nucleocapsid were
obtained by immunization of llamas with recombinant protein
(Serruys et al., 2010). Following two rounds of panning 6 Nanobodies were selected and their binding properties characterized. The
binding affinity of three Nanobodies (C2, C4 and C6) to HBcAg
was comparable with that of a reference mAb. Two Nanobodies
(C4 and C6) also recognized the HBeAg antigen. This secreted protein shares a large part of its amino acid sequence with HBcAg. Despite difference in conformation and sequence, HBeAg and HBcAg
share indeed some antigenic epitopes. Nanobodies C2, C4 and C6
were also shown to recognize two HBcAg variants. Because the
nucleocapsids have different functions in different cellular compartments, the coding sequences of C2, C4 and C6 were cloned expressed either in the cytoplasm or targeted to the nucleus. The
latter was obtained by adding a triple nuclear localization signal
(NLS) form the SV40 large T antigen. Confocal microscopy demonstrated indeed that the Nanobodies without this NLS were found in
the cytoplasm. Nanobodies with an NLS were detected in the nucleus. Co-expression of cytoplasmic Nanobodies with HBV had no
visible effect on the cellular distribution of nucleocapsids. A diffuse
cytoplasmic staining was observed. Unexpectedly, co-expression of
HBV with the nuclear Nanobodies caused a more intense speckled
nucleocapsid staining in the cytoplasm. No nucleocapsid staining
was observed in the nucleus. The cytoplasmic or nuclear presence
of Nanobodies did not reduce or enhance secretion of S proteins
and HBeAg. However an increase in intracellular HBeAg was observed when Nanobodies C2 and C6 were present in the nucleus.
Even more surprisingly was the observation that only in lysates
of cells expressing the cytoplasmic Nanobodies, nucleocapsids
were detected by ELISA. Nucleocapsids were no longer detected
when the nuclear Nanobodies were present. While in this study
it was not demonstrate that nucleocapsid Nanobodies inhibited
viral replication, these did reveal that targeting these Nanobodies
to the nucleus have an effect on the expression and intracellular
trafficking of nucleocapsids and HBeAg.
402
P. Vanlandschoot et al. / Antiviral Research 92 (2011) 389–407
3.8.3. Porcine endogenous retrovirus (PERV) Nanobodies
To solve the shortage of human organs for transplantation, the
use of organs from other species is considered. The preferred donor
species is the pig (Sus scrofa) due to the anatomical and physiological similarities. Also the lower risk of transmissible infectious diseases when compared to primates is a widely used argument.
While specific pathogen-free breeding might solve this problem
for known pathogens, this is less obvious for the in the pig genome
encoded endogenous retroviruses (PERV). There are 50 proviral
integration sites in the genome, but elimination by knock out or
breeding is impossible. Three classes of PERVs (A, B and C) have
been identified (Le Tissier et al., 1997; Takeuchi et al., 1998; Patience et al., 2001). PERV-A and PERV-B are able to infect human
cells in vitro. PERVs can infect mouse cells in vivo, but long term
infection of humans after transplantation has not been demonstrated (Patience et al., 1997; Takeuchi et al., 1998; Paradis et al.,
1999; Czauderna et al., 2000; Deng et al., 2000; van der Laan
et al., 2000; Specke et al., 2001). Nevertheless, the potential risk
for infection and spread of infectious PERVs beyond the xenotransplant recipient cannot be excluded (reviewed in (Denner, 2011).
The GAG and POL genes, but not the envelope genes, from the A,
B and C PERVs show high homology (Takeuchi et al., 1998). For this
reason llamas were immunized with a recombinant 60 kDa GAG
protein produced in E. coli (Dekker et al., 2003). This GAG protein
was derived from a B type PERV from the porcine PK15 cell line.
Sera recognized the 60 kDa precursor but also all intermediate
and mature forms of the GAG proteins: major capsid (p27), matrix
(p15), inner coat and nucleocapsid protein. Following selection and
screening on purified GAG protein, eight Nanobodies were obtained. These Nanobodies not only recognized the recombinant
GAG protein, but also GAG protein form porcine cell lysates and
virus. Two Nanobodies were shown to bind p27, while the other
6 recognized the p15 protein. To test the capacity of the Nanobodies to reduce viral replication, three Nanobodies were stably expressed in the cytoplasm of PK15 cell line using the TET-on
expression system. In these cells, the GAG protein is detected in
a punctuate staining at the plasma membrane when no Nanobodies are present. In the presence of two Nanobodies A5 and E11, this
(punctuate) staining was not detected. Western blotting analysis
demonstrated the rapid disappearance of the precursor GAG and
p27 proteins. The activity of the Reverse transcriptase was also reduced strongly only when A5 and E11 were expressed. Expression
of the third Nanobody D2, which binds p27 did not reduce GAG
and RT activity. Finally it was demonstrated that production of cell
free PERV-A and PERV-B viral particles was reduced in the presence
of the A5 Nanobody.
To avoid hyper acute rejection of the transplanted organ, pigs
have been obtained in which the a-1,3 galactosyltransferase gene
has been knocked out (Dai et al., 2002; Lai et al., 2002; Phelps
et al., 2003). In addition pigs transgenic for human complement
regulatory proteins have been generated (Platt, 2002). While
reducing hyper acute rejection, these modifications also potentially increase the risk for xenozoonosis caused by PERVs. The
transgenic intracellular expression of the inhibitory GAG-specific
Nanobodies in pigs might represent an elegant solution of the PERV
safety problem.
4. Diagnostic applications
4.1. Vaccinia virus and Marburg virus VHHs
The remarkable heat stability and refolding capacity of VHHs
has spurred the idea to use VHHs in rugged diagnostic assays to
be used in resource-poor and remote settings where reliable cold
chains are lacking. This was considered to be of importance to
detect bio-threat targets and/or emerging viruses like smallpox
virus and filoviruses. To isolate VHHs binding vaccinia virus, a
smallpox virus surrogate, a highly diverse library was generated
starting from a 106 member non-immune library (Goldman et al.,
2006). Error prone PCR was followed by PCR segmentation and
fragment reshuffling. This resulted in a library of 109 individual
VHH members. Selections were performed on coated purified vaccinia virus (strain Western Reserve). After panning and screening 7
unique VHHs binding vaccinia virus were identified. Two VHHS,
called G and D showed significant binding to vaccinia virus in ELISA
and did not cross-react with SARS and an influenza virus. This
demonstrated the selectivity of the two VHHs for vaccinia virus.
After a 5 min incubation of the VHHs at a temperature between
95 and 100 °C, the two VHHS retained their binding capacity. In
comparison, the binding ability of conventional antibodies and
scFv was rapidly lost even after incubation at 60 or 75 °C. Even
after incubation at 95 °C for 40 min, clone G retained 40% of its
activity. Only 3% of the activity was retained after incubation for
80 min.
Marburg virus and Ebola virus belong to the filovirus family
and are causative agents of hemorrhagic fever often resulting in
a fatal outcome in humans. These viruses cause sporadic outbreaks in Sub-Saharan Africa (Peterson et al., 2004). Highly sensitive, specific and rapid diagnostics are crucial for an adequate
response to viral outbreaks of this nature. Using phage display,
Sherwood and colleagues were able to select Marburg specific
Nanobodies, not cross-reactive to Ebola virus, from a semi-synthetic library (Sherwood et al., 2007). In addition, they developed
a Marburg virus specific antigen capture assay and this all in less
than 3 weeks in a biosafety level 4 (BSL4) environment. The rapid
assay development was made possible by the use of a synthetic
library, phage display and purification of polyhistidine tagged
Nanobodies from prokaryotic expression systems which bypassed
the need for time consuming immunization and hybridoma production typically associated with mAb generation. The most sensitive assay using chemiluminescence and phage displayed
Nanobodies could detect virus as low as 0.1–1 pfu/ml which
was superior over RT-PCR. As the initial library contained heat
stable Nanobodies the authors developed a second assay using labeled purified Nanobodies for virus detection. Such reagents are
considered essential for diagnosis in remote settings for which a
cold chain may not be feasible.
In conclusion, Nanobodies are promising reagents for viral
diagnosis and have clear advantages in difficult environments
such as BSL4 and field testing without the need for reagent
refrigeration.
4.2. Plant virus VHHs
Tulip virus X (TuVX), a flexuous filamentous particles, is a positive-stranded RNA virus belonging to the family of flexiviridae. It is
a mechanically transmissible virus that causes chlorotic and necrotic lesions in leaves and streaks of intensified pigmentation in
tepals of tulip plants. Several governments consider this virus as
a pathogen of potential quarantine concern on flower bulb imports; therefore it is necessary to have tools that allow its reliable
and fast identification to test the phytosanitary status of large
volumes of plant material for trade. Traditionally, immunological
tests for detection of plant viruses have involved the use of antiserum raised in rabbit, chicken or mouse. However, Beekwilder and
colleagues developed a novel immunological detection tool, base
on VHHs, to identify TuVX-infected tulip leaf (Beekwilder et al.,
2008). They immunized alpacas with TuVX particles and selected
28 positive clones by phage display, which were subsequently
grouped in five sequence groups by variations in the CDR regions.
The specificity of these clones to TuVX was investigated using an
P. Vanlandschoot et al. / Antiviral Research 92 (2011) 389–407
ELISA test, they compared the binding properties of VHHs to
different members of the flexiviridae family such as Potato virus
S, Potato virus X, Kalanchoe mosaic virus, Pepino mosaic virus,
and the carlavirus Chrysanthemum virus B. They were able to confirm that VHHs were specific for TuVX. They also tested one of the
VHHs in a double antibody sandwich ELISA tests (DAS-ELISA), a
routinely used technique. Virus particles and leaf extract were
tested in different dilutions, significant signals were observed with
both kind of samples and the detection limit was comparable to
that of other serological virus tests.
5. Industrial applications
5.1. Lactococcus bacteriophage VHH
Lactic acid bacteria such as Lactococcus lactis have been used for
centuries for the industrial production of fermented dairy products. A major and critical factor in this process is the risk of lysis
of the milk-fermenting lactic acid bacteria by bacteriophages, an
event that leads to delays in the milk fermentation process or even
failure. Lactococcal phages have a head structure, containing the
double-stranded DNA genome, and a tail, which is involved in host
recognition. Based on DNA sequence homology, 3 groups of lactococcal phages are discerned: 936-, c2- and P335-like phages (Moineau, 1999). One theoretical way to reduce infection of the milkfermenting lactococci by lytic bacteriophages would be the use of
neutralizing agents that can prevent binding of phages to their
receptors expressed on the bacterial surface. However, a practical
concern is that these neutralizing agents, apart from being highly
effective, should be applicable at the vast scale of industrial milk
fermentors and be cost-effective. For such an application heavychain antibodies appeared to be very well suited since they can
easily be produced in gram amounts in gram-positive and -negative bacteria or in lower eukaryotes such as S. cerevisiae (a GRAS
organism), ensuring a low production cost.
The lactococcal bacteriophage p2 (group 936 phage) was selected to isolate and functionally characterize such VHHs (Ledeboer et al., 2002; De Haard et al., 2005). A llama was immunized
with purified p2 bacteriophages for the generation of a phage
M13 library to display the VHH-repertoire of the animal. By combining conventional biopanning against immobilized p2 phage
with a p2 phage neutralization assay, three neutralizing and four
non-neutralizing VHH antibody producing clones were isolated
(De Haard et al., 2005). The neutralizing VHH fragments had a similar sequence and therefore presumably recognized the same epitope in p2, whereas the non-neutralizing VHH fragments were
more divergent. Both types of VHHs were subsequently produced
in S. cerevisiae and purified for further characterization. One of
the VHHs (VHH5) neutralized the infectivity of p2 phage applied
at a load of 103–105 plaque-forming units/ml, at a concentration
as low as 2.25 nM. This value agreed well with the affinity of
1.4 nM (KD, as measured by surface plasmon resonance). Using immuno-electron microscopy analysis, De Haard and colleagues demonstrated that VHH5 recognized the tip to the p2 phage tail,
whereas a non-neutralizing VHH2 bound to ORF11, the major
structural protein of the phage head. The tip of head-and-tail bacteriophages is typically involved in bacterial host cell recognition
and hence this recognition agrees well with the neutralizing activity of VHH5. The target epitope of this neutralizing VHH was further characterized by Western blot analysis and characterization
of purified recombinant p2 phage ORF18, a protein located at the
tip of the tail. In fact the neutralizing Nanobodies were instrumental in elucidating the role of ORF18 in 936-type bacteriophage biology (Tremblay et al., 2006). The structure of the p2 receptor
binding protein was finally solved and to show similarity proteins
403
form other bacterial and mammalian viruses. The structure of the
receptor binding site on p2 was identified by solving the structure
of p2, complexed with VVH5 (Spinelli et al., 2006).
In a follow up study, VHH2 and VHH5 were produced in L. paracasei, a Gram-positive bacterium that is also used in the milk fermentation industry, e.g. for the production of cheese (Hultberg
et al., 2007). VHH5 secreted by the recombinant L. paracasei retained its capacity to neutralize bacteriophage p2. Interestingly,
also the non-neutralizing VHH2 could inhibit the infectivity of
p2, by expressing this VHH on the surface of L. paracasei. Most
likely, phage p2 particles are trapped by the surface-anchored
VHH2 on L. paracasei cells, as was demonstrated by scanning electron microscopy (Hultberg et al., 2007). This result demonstrated
that also VHHs, not recognizing the receptor binding protein, could
be applied to prevent infection milk-fermenting lactic with
bacteriophages.
Taken together, bacteriophage neutralizing VHH can be used in
industrial milk-fermentation processes such as cheese production,
to protect the microbial starter culture against lysis by bacteriophages. Such VHHs can be produced in GRAS organisms, including
milk-fermenting bacteria, either as secreted antibody-fragments or
as surface anchored baits.
6. Conclusion
While VHH share the high selectivity, specificity and affinities of
conventional antibodies, their smaller size, heightened stability,
solubility and modularity give them unparalleled advantages for
drug development and other applications. Although heavy chainonly antibodies in Camelidae were discovered more than 20 years
ago, it was not until 2002 before the first VHHs directed against
a virus (bacteriophage) were reported. One year later the first
Nanobody directed against a mammalian virus (PERV) was described. Since then, the list of viruses and viral proteins for which
Nanobodies have been raised is growing steadily. However, form
the work published one might indeed think of Nanobodies as
‘‘new ammunition to battle viruses’’. Antiviral Nanobodies with
nanomolar neutralization potencies are isolated after immunization. However, picomolar neutralization potencies are easily obtained by simple genetic multmerization of Nanobodies.
Multimerization can also be used to generate broadly neutralizing
Nanobodies which is important when dealing with highly variable
viruses like HIV and influenza. The fusion of Nanobodies that recognize different neutralizing epitopes might even reduce the
change of viral escape during treatment. The Nanobodies can be
delivered into the pulmonary and gastro-intestinal tract instead
of being injected peripherally. This allows very high dosing in the
relevant infected organ or tissue. The advantage of Nanobodies as
antiviral intrabodies has been recognized very early on. In fact,
the first successful intrabody-mediated inhibition of viral replication in vivo was obtained with a Nanobody. However the successful
application of intra-Nanobodies in patients requires more efficient
and safe delivery tools. Viral delivery seems to be the most advanced methodology.
Several Nanobodies have entered clinical trials the last few
years. An RSV neutralizing Nanobody is expected to enter phase I
clinical trial during the course of 2011. Of note, this Nanobody is
planned to be delivered via the lungs (see www.Ablynx.com). A
cause for concern for the use of Nanobodies is of course their llama
origin. However, to reduce the risk of immunogenicity, Nanobodies
can be humanized (Vincke et al., 2009). This is a straightforward
procedure because Nanobodies already display relatively high sequence homology to human heavy chain variable domains. However, similarly to conventional antibodies, immunogenicity needs
to be assessed on a case by case basis in the clinical setting.
404
P. Vanlandschoot et al. / Antiviral Research 92 (2011) 389–407
Disclosure statement
P.V., C.S., E.D. are employees of ABlynx NV. E.B. is a former employee of Ablynx. P.V., C.S., E.D., E.B. own Ablynx stocks or warrants. P.V., C.S., E.D., E.B., X.S. and B.S. are inventors on patent
applications owned by Ablynx NV.
Acknowledgements
The authors would like to thank all the colleagues at Ablynx and
our academic collaborators who have contributed to the antiviral
Nanobody work mentioned in this paper. Part of the work performed by Ablynx and our collaborators was supported by the
Institute for the Promotion of Innovation by Science and technology in Flanders Ghent (IWT70050) from the Flemish government.
References
Van den Abbeele, A., De Clercq, S., De Ganck, A., De Corte, V., Van Loo, B., Soror, S.H.,
Srinivasan, V., Steyaert, J., Vandekerckhove, J., Gettemans, J., 2010. A llamaderived gelsolin single-domain antibody blocks gelsolin-G-actin interaction.
Cell. Mol. Life Sci. 67, 1519–1535.
Barbas 3rd, C.F., Björling, E., Chiodi, F., Dunlop, N., Cababa, D., Jones, T.M., Zebedee,
S.L., Persson, M.A., Nara, P.L., Norrby, E., 1992. Recombinant human Fab
fragments neutralize human type 1 immunodeficiency virus in vitro. Proc. Natl.
Acad. Sci. USA 89, 9339–9343.
Beekwilder, J., Houwelingen, A., Beckhoven, J., Speksnijder, A., 2008. Stable
recombinant alpaca antibodies for detection of Tulip virus X. Eur. J. Plant
Pathol. 121, 477–485.
Binley, J.M., Wrin, T., Korber, B., Zwick, M.B., Wang, M., Chappey, C., Stiegler, G.,
Kunert, R., Zolla-Pazner, S., Katinger, H., Petropoulos, C.J., Burton, D.R., 2004.
Comprehensive cross-clade neutralization analysis of a panel of anti-human
immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78,
13232–13252.
Van Bockstaele, F., Holz, J.-B., Revets, H., 2009. The development of nanobodies for
therapeutic applications. Curr. Opin. Investig. Drugs 10, 1212–1224.
Bouchet, J., Basmaciogullari, S.E., Chrobak, P., Stolp, B., Bouchard, N., Fackler, O.T.,
Chames, P., Jolicoeur, P., Benichou, S., Baty, D., 2011. Inhibition of the Nef
regulatory protein of HIV-1 by a single-domain antibody. Blood 117,
3559–3568.
Bruss, V., 2007. Hepatitis B virus morphogenesis. World J. Gastroenterol. 13, 65–73.
Buchacher, A., Predl, R., Strutzenberger, K., Steinfellner, W., Trkola, A., Purtscher, M.,
Gruber, G., Tauer, C., Steindl, F., Jungbauer, A., 1994. Generation of human
monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr
virus transformation for peripheral blood lymphocyte immortalization. AIDS
Res. Hum. Retroviruses 10, 359–369.
Burns, J.W., Siadat-Pajouh, M., Krishnaney, A.A., Greenberg, H.B., 1996. Protective
effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing
activity. Science 272, 104–107.
Burton, D.R., Barbas 3rd, C.F., Persson, M.A., Koenig, S., Chanock, R.M., Lerner, R.A.,
1991. A large array of human monoclonal antibodies to type 1 human
immunodeficiency virus from combinatorial libraries of asymptomatic
seropositive individuals. Proc. Natl. Acad. Sci. USA 88, 10134–10137.
Burton, D.R., Pyati, J., Koduri, R., Sharp, S.J., Thornton, G.B., Parren, P.W., Sawyer, L.S.,
Hendry, R.M., Dunlop, N., Nara, P.L., 1994. Efficient neutralization of primary
isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266,
1024–1027.
Calder, L.J., González-Reyes, L., García-Barreno, B., Wharton, S.A., Skehel, J.J., Wiley,
D.C., Melero, J.A., 2000. Electron microscopy of the human respiratory syncytial
virus fusion protein and complexes that it forms with monoclonal antibodies.
Virology 271, 122–131.
Conrath, K.E., Lauwereys, M., Galleni, M., Matagne, A., Frère, J.M., Kinne, J., Wyns, L.,
Muyldermans, S., 2001a. Beta-lactamase inhibitors derived from single-domain
antibody fragments elicited in the Camelidae. Antimicrob. Agents Chemother.
45, 2807–2812.
Conrath, K., Lauwereys, M., Wyns, L., Muyldermans, S., 2001b. Camel single-domain
antibodies as modular building units in bispecific and bivalent antibody
constructs. J. Biol. Chem. 276, 7346–7350.
Conrath, K., Pereira, A.S., Martins, C.E., Timóteo, C.G., Tavares, P., Spinelli, S., Kinne, J.,
Flaudrops, C., Cambillau, C., Muyldermans, S., Moura, I., Moura, J.J.G., Tegoni, M.,
Desmyter, A., 2009. Camelid nanobodies raised against an integral membrane
enzyme, nitric oxide reductase. Protein Sci. 18, 619–628.
Coppieters, K., Dreier, T., Silence, K., de Haard, H., Lauwereys, M., Casteels, P.,
Beirnaert, E., Jonckheere, H., Van de Wiele, C., Staelens, L., Hostens, J., Revets, H.,
Remaut, E., Elewaut, D., Rottiers, P., 2006. Formatted anti-tumor necrosis factor
alpha VHH proteins derived from camelids show superior potency and targeting
to inflamed joints in a murine model of collagen-induced arthritis. Arthritis
Rheum. 54, 1856–1866.
Corthésy, B., Benureau, Y., Perrier, C., Fourgeux, C., Parez, N., Greenberg, H.,
Schwartz-Cornil, I., 2006. Rotavirus anti-VP6 secretory immunoglobulin A
contributes to protection via intracellular neutralization but not via immune
exclusion. J. Virol. 80, 10692–10699.
Czauderna, F., Fischer, N., Boller, K., Kurth, R., Tönjes, R.R., 2000. Establishment and
characterization of molecular clones of porcine endogenous retroviruses
replicating on human cells. J. Virol. 74, 4028–4038.
Daelemans, D., Costes, S.V., Lockett, S., Pavlakis, G.N., 2005. Kinetic and molecular
analysis of nuclear export factor CRM1 association with its cargo in vivo. Mol.
Cell. Biol. 25, 728–739.
Dai, Y., Vaught, T.D., Boone, J., Chen, S.-H., Phelps, C.J., Ball, S., Monahan, J.A., Jobst,
P.M., McCreath, K.J., Lamborn, A.E., Cowell-Lucero, J.L., Wells, K.D., Colman, A.,
Polejaeva, I.A., Ayares, D.L., 2002. Targeted disruption of the alpha1, 3galactosyltransferase gene in cloned pigs. Nat. Biotechnol. 20, 251–255.
Daley, L.P., Kutzler, M.A., Bennett, B.W., Smith, M.C., Glaser, A.L., Appleton, J.A., 2010.
Effector functions of camelid heavy-chain antibodies in immunity to West Nile
virus. Clin. Vaccine Immunol. 17, 239–246.
Daley-Bauer, L.P., Purdy, S.R., Smith, M.C., Gagliardo, L.F., Davis, W.C., Appleton, J.A.,
2010. Contributions of conventional and heavy-chain IgG to immunity in fetal,
neonatal, and adult alpacas. Clin. Vaccine Immunol. 17, 2007–2015.
Dalgleish, A.G., Beverley, P.C., Clapham, P.R., Crawford, D.H., Greaves, M.F., Weiss,
R.A., 1984. The CD4 (T4) antigen is an essential component of the receptor for
the AIDS retrovirus. Nature 312, 763–767.
Dekker, S., Toussaint, W., Panayotou, G., de Wit, T., Visser, P., Grosveld, F., Drabek, D.,
2003. Intracellularly expressed single-domain antibody against p15 matrix
protein prevents the production of porcine retroviruses. J. Virol. 77,
12132–12139.
Deng, Y.M., Tuch, B.E., Rawlinson, W.D., 2000. Transmission of porcine endogenous
retroviruses in severe combined immunodeficient mice xenotransplanted with
fetal porcine pancreatic cells. Transplantation 70, 1010–1016.
Denner, J., 2011. Infectious risk in xenotransplantation – what post-transplant
screening for the human recipient? Xenotransplantation 18, 151–157.
Deschacht, N., De Groeve, K., Vincke, C., Raes, G., De Baetselier, P., Muyldermans, S.,
2010. A novel promiscuous class of camelid single-domain antibody contributes
to the antigen-binding repertoire. J. Immunol. 184, 5696–5704.
Desmyter, A., Decanniere, K., Muyldermans, S., Wyns, L., 2001. Antigen specificity
and high affinity binding provided by one single loop of a camel single-domain
antibody. J. Biol. Chem. 276, 26285–26290.
Desmyter, A., Transue, T.R., Ghahroudi, M.A., Thi, M.H., Poortmans, F., Hamers, R.,
Muyldermans, S., Wyns, L., 1996. Crystal structure of a camel single-domain VH
antibody fragment in complex with lysozyme. Nat. Struct. Biol. 3, 803–811.
Dolk, E., van der Vaart, M., Lutje Hulsik, D., Vriend, G., de Haard, H., Spinelli, S.,
Cambillau, C., Frenken, L., Verrips, T., 2005. Isolation of llama antibody
fragments for prevention of dandruff by phage display in shampoo. Appl.
Environ. Microbiol. 71, 442–450.
Dumoulin, M., Conrath, K., Van Meirhaeghe, A., Meersman, F., Heremans, K.,
Frenken, L.G.J., Muyldermans, S., Wyns, L., Matagne, A., 2002. Single-domain
antibody fragments with high conformational stability. Protein Sci. 11,
500–515.
Ewert, S., Cambillau, C., Conrath, K., Plückthun, A., 2002. Biophysical properties of
camelid V(HH) domains compared to those of human V(H)3 domains.
Biochemistry 41, 3628–3636.
Falsey, A.R., Cunningham, C.K., Barker, W.H., Kouides, R.W., Yuen, J.B., Menegus,
M., Weiner, L.B., Bonville, C.A., Betts, R.F., 1995. Respiratory syncytial virus
and influenza A infections in the hospitalized elderly. J. Infect. Dis. 172,
389–394.
Feld, J., Lee, J.-yeeLocarnini, S., 2003. New targets and possible new therapeutic
approaches in the chemotherapy of chronic hepatitis B. Hepatology 38,
545–553.
Fischer, U., Huber, J., Boelens, W.C., Mattaj, I.W., Lührmann, R., 1995. The HIV-1 Rev
activation domain is a nuclear export signal that accesses an export pathway
used by specific cellular RNAs. Cell 82, 475–483.
Fornerod, M., Ohno, M., Yoshida, M., Mattaj, I.W., 1997. CRM1 is an export receptor
for leucine-rich nuclear export signals. Cell 90, 1051–1060.
Forsman, A., Beirnaert, E., Aasa-Chapman, M.M.I., Hoorelbeke, B., Hijazi, K., Koh, W.,
Tack, V., Szynol, A., Kelly, C., McKnight, A., Verrips, T., de Haard, H., Weiss, R.A.,
2008. Llama antibody fragments with cross-subtype human immunodeficiency
virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J.
Virol. 82, 12069–12081.
Foster, J.L., Garcia, J.V., 2008. HIV-1 Nef: at the crossroads. Retrovirology 5, 84.
Fukuda, M., Asano, S., Nakamura, T., Adachi, M., Yoshida, M., Yanagida, M., Nishida,
E., 1997. CRM1 is responsible for intracellular transport mediated by the
nuclear export signal. Nature 390, 308–311.
Garaicoechea, L., Olichon, A., Marcoppido, G., Wigdorovitz, A., Mozgovoj, M., Saif, L.,
Surrey, T., Parreño, V., 2008. Llama-derived single-chain antibody fragments
directed to rotavirus VP6 protein possess broad neutralizing activity in vitro
and confer protection against diarrhea in mice. J. Virol. 82, 9753–9764.
De Genst, E., Silence, K., Decanniere, K., Conrath, K., Loris, R., Kinne, J., Muyldermans,
S., Wyns, L., 2006. Molecular basis for the preferential cleft recognition by
dromedary heavy-chain antibodies. Proc. Natl. Acad. Sci. USA 103, 4586–4591.
Goldman, E.R., Anderson, G.P., Liu, J.L., Delehanty, J.B., Sherwood, L.J., Osborn, L.E.,
Cummins, L.B., Hayhurst, A., 2006. Facile generation of heat-stable antiviral and
antitoxin single domain antibodies from a semisynthetic llama library. Anal.
Chem. 78, 8245–8255.
Goudsmit, J., Marissen, W.E., Weldon, W.C., Niezgoda, M., Hanlon, C.A., Rice, A.B.,
Kruif, J., de Dietzschold, B., Bakker, A.B.H., Rupprecht, C.E., 2006. Comparison of
an anti-rabies human monoclonal antibody combination with human
polyclonal anti-rabies immune globulin. J. Infect. Dis 193, 796–801.
P. Vanlandschoot et al. / Antiviral Research 92 (2011) 389–407
Greenberg, A.S., Avila, D., Hughes, M., McKinney, E.C., Flajnik, M.F., 1996. A new
antigen receptor gene family that undergoes rearrangement and extensive
somatic diversification in sharks. Nature 374, 168–173.
Groot, A.J., Verheesen, P., Westerlaken, E.J., Gort, E.H., van der Groep, P., Bovenschen,
N., van der Wall, E., van Diest, P.J., Shvarts, A., 2006. Identification by phage
display of single-domain antibody fragments specific for the ODD domain in
hypoxia-inducible factor 1alpha. Lab. Invest. 86, 345–356.
Groothuis, J.R., Simoes, E.A., Levin, M.J., Hall, C.B., Long, C.E., Rodriguez, W.J., Arrobio,
J., Meissner, H.C., Fulton, D.R., Welliver, R.C., 1993. Prophylactic administration
of respiratory syncytial virus immune globulin to high-risk infants and young
children. The respiratory syncytial virus immune globulin study group. N. Engl.
J. Med. 329, 1524–1530.
Gualtero, D.F., Guzmán, F., Acosta, O., Guerrero, C.A., 2007. Amino acid domains
280–297 of VP6 and 531–554 of VP4 are implicated in heat shock cognate
protein hsc70-mediated rotavirus infection. Arch. Virol. 152, 2183–2196.
De Haard, H.J.W., Bezemer, S., Ledeboer, A.M., Müller, W.H., Boender, P.J., Moineau,
S., Coppelmans, M.-C., Verkleij, A.J., Frenken, L.G.J., Verrips, C.T., 2005. Llama
antibodies against a lactococcal protein located at the tip of the phage tail
prevent phage infection. J. Bacteriol. 187, 4531–4541.
Hall, C.B., 2001. Respiratory syncytial virus and parainfluenza virus. N. Engl. J. Med.
344, 1917–1928.
Hall, C.B., Weinberg, G.A., Iwane, M.K., Blumkin, A.K., Edwards, K.M., Staat, M.A.,
Auinger, P., Griffin, M.R., Poehling, K.A., Erdman, D., Grijalva, C.G., Zhu, Y.,
Szilagyi, P., 2009. The burden of respiratory syncytial virus infection in young
children. N. Engl. J. Med. 360, 588–598.
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hamers, C.,
Songa, E.B., Bendahman, N., Hamers, R., 1993. Naturally occurring antibodies
devoid of light chains. Nature 363, 446–448.
Hanna, Z., Kay, D.G., Rebai, N., Guimond, A., Jothy, S., Jolicoeur, P., 1998. Nef harbors
a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1
in transgenic mice. Cell 95, 163–175.
Harmsen, M.M., De Haard, H.J., 2007. Properties, production, and applications of
camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 77,
13–22.
Harmsen, M.M., Ruuls, R.C., Nijman, I.J., Niewold, T.A., Frenken, L.G., de Geus, B.,
2000. Llama heavy-chain V regions consist of at least four distinct subfamilies
revealing novel sequence features. Mol. Immunol. 37, 579–590.
Harmsen, M.M., Van Solt, C.B., Fijten, H.P.D., Van Setten, M.C., 2005. Prolonged
in vivo residence times of llama single-domain antibody fragments in pigs by
binding to porcine immunoglobulins. Vaccine 23, 4926–4934.
Harmsen, M.M., van Solt, C.B., van Zijderveld-van Bemmel, A.M., Niewold, T.A., van
Zijderveld, F.G., 2006. Selection and optimization of proteolytically stable llama
single-domain antibody fragments for oral immunotherapy. Appl. Microbiol.
Biotechnol. 72, 544–551.
Harmsen, M.M., van Solt, C.B., Fijten, H.P.D., van Keulen, L., Rosalia, R.A.,
Weerdmeester, K., Cornelissen, A.H.M., De Bruin, M.G.M., Eblé, P.L., Dekker,
A., 2007. Passive immunization of guinea pigs with llama single-domain
antibody fragments against foot-and-mouth disease. Vet. Microbiol. 120,
193–206.
Harmsen, M.M., Fijten, H.P.D., Dekker, A., Eblé, P.L., 2008. Passive immunization of
pigs with bispecific llama single-domain antibody fragments against foot-andmouth disease and porcine immunoglobulin. Vet. Microbiol. 132, 56–64.
Harmsen, M.M., van Solt, C.B., Fijten, H.P.D., 2009a. Enhancement of toxin- and
virus-neutralizing capacity of single-domain antibody fragments by Nglycosylation. Appl. Microbiol. Biotechnol. 84, 1087–1094.
Harmsen, M.M., Fijten, H.P.D., Engel, B., Dekker, A., Eblé, P.L., 2009b. Passive
immunization with llama single-domain antibody fragments reduces foot-andmouth disease transmission between pigs. Vaccine 27, 1904–1911.
Hemming, V.G., Prince, G.A., Horswood, R.L., London, W.J., Murphy, B.R., Walsh, E.E.,
Fischer, G.W., Weisman, L.E., Baron, P.A., Chanock, R.M., 1985. Studies of passive
immunotherapy for infections of respiratory syncytial virus in the respiratory
tract of a primate model. J. Infect. Dis. 152, 1083–1087.
Henderson, F.W., Collier, A.M., Clyde Jr., W.A., Denny, F.W., 1979. Respiratorysyncytial-virus infections, reinfections and immunity. A prospective,
longitudinal study in young children. N. Engl. J. Med 300, 530–534.
Hilleman, M.R., 2003. Critical overview and outlook: pathogenesis, prevention, and
treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus.
Vaccine 21, 4626–4649.
Hinz, A., Lutje Hulsik, D., Forsman, A., Koh, W.W.-L., Belrhali, H., Gorlani, A., de
Haard, H., Weiss, R.A., Verrips, T., Weissenhorn, W., 2010. Crystal structure of
the neutralizing Llama V(HH) D7 and its mode of HIV-1 gp120 interaction. PLoS
ONE 5, e10482.
Hmila, I., Saerens, D., Ben Abderrazek, R., Vincke, C., Abidi, N., Benlasfar, Z., Govaert,
J., El Ayeb, M., Bouhaouala-Zahar, B., Muyldermans, S., 2010. A bispecific
Nanobody to provide full protection against lethal scorpion envenoming. FASEB
J. 24, 3479–3489.
Holliger, P., Hudson, P.J., 2005. Engineered antibody fragments and the rise of single
domains. Nat. Biotechnol. 23, 1126–1136.
Hultberg, A., Temperton, N.J., Rosseels, V., Koenders, M., Gonzalez-Pajuelo, M.,
Schepens, B., Ibañez, L.I., Vanlandschoot, P., Schillemans, J., Saunders, M., Weiss,
R.A., Saelens, X., Melero, J.A., Verrips, C.T., Van Gucht, S., de Haard, H.J., 2011.
Llama-derived single domain antibodies to build multivalent, superpotent and
broadened neutralizing anti-viral molecules. PLoS ONE 6, e17665.
Hultberg, A., Tremblay, D.M., de Haard, H., Verrips, T., Moineau, S., Hammarström, L.,
Marcotte, H., 2007. Lactobacillli expressing llama VHH fragments neutralise
Lactococcus phages. BMC Biotechnol. 7, 58.
405
Ibañez, L.I., De Filette, M., Hultberg, A., Verrips, T., Temperton, N., Weiss, R.A.,
Vandevelde, W., Schepens, B., Vanlandschoot, P., Saelens, X., 2011. Nanobodies
with in vitro neutralizing activity protect mice against H5N1 influenza virus
infection. J. Infect. Dis. 203, 1063–1072.
Jähnichen, S., Blanchetot, C., Maussang, D., Gonzalez-Pajuelo, M., Chow, K.Y., Bosch,
L., De Vrieze, S., Serruys, B., Ulrichts, H., Vandevelde, W., Saunders, M., De Haard,
H.J., Schols, D., Leurs, R., Vanlandschoot, P., Verrips, T., Smit, M.J., 2010. CXCR4
nanobodies (VHH-based single variable domains) potently inhibit chemotaxis
and HIV-1 replication and mobilize stem cells. Proc. Natl. Acad. Sci. USA 107,
20565–20570.
Johnson, S., Oliver, C., Prince, G.A., Hemming, V.G., Pfarr, D.S., Wang, S.C., Dormitzer,
M., O’Grady, J., Koenig, S., Tamura, J.K., Woods, R., Bansal, G., Couchenour, D.,
Tsao, E., Hall, W.C., Young, J.F., 1997. Development of a humanized monoclonal
antibody (MEDI-493) with potent in vitro and in vivo activity against
respiratory syncytial virus. J. Infect. Dis. 176, 1215–1224.
Kann, M., Schmitz, A., Rabe, B., 2007. Intracellular transport of hepatitis B virus.
World J. Gastroenterol. 13, 39–47.
Klatzmann, D., Champagne, E., Chamaret, S., Gruest, J., Guetard, D., Hercend, T.,
Gluckman, J.C., Montagnier, L., 1984. T-lymphocyte T4 molecule behaves as the
receptor for human retrovirus LAV. Nature 312, 767–768.
Klooster, R., Eman, M.R., le Duc, Q., Verheesen, P., Verrips, C.T., Roovers, R.C., Post,
J.A., 2009. Selection and characterization of KDEL-specific VHH antibody
fragments and their application in the study of ER resident protein
expression. J. Immunol. Methods 342, 1–12.
Knobel, D.L., Cleaveland, S., Coleman, P.G., Fèvre, E.M., Meltzer, M.I., Miranda, M.E.G.,
Shaw, A., Zinsstag, J., Meslin, F.-X., 2005. Re-evaluating the burden of rabies in
Africa and Asia. Bull. World Health Organ. 83, 360–368.
Koh, W.W.L., Steffensen, S., Gonzalez-Pajuelo, M., Hoorelbeke, B., Gorlani, A.,
Szynol, A., Forsman, A., Aasa-Chapman, M.M.I., de Haard, H., Verrips, T.,
Weiss, R.A., 2010. Generation of a family-specific phage library of llama
single chain antibody fragments that neutralize HIV-1. J. Biol. Chem. 285,
19116–19124.
Kolkman, J.A., Law, D.A., 2010. Nanobodies-from llamas to therapeutic proteins.
Drug Discov. Today: Technol. 7, e139–e146.
van der Laan, L.J., Lockey, C., Griffeth, B.C., Frasier, F.S., Wilson, C.A., Onions, D.E.,
Hering, B.J., Long, Z., Otto, E., Torbett, B.E., Salomon, D.R., 2000. Infection by
porcine endogenous retrovirus after islet xenotransplantation in SCID mice.
Nature 407, 90–94.
Lai, L., Kolber-Simonds, D., Park, K.-W., Cheong, H.-T., Greenstein, J.L., Im, G.-S.,
Samuel, M., Bonk, A., Rieke, A., Day, B.N., Murphy, C.N., Carter, D.B., Hawley, R.J.,
Prather, R.S., 2002. Production of alpha-1,3-galactosyltransferase knockout pigs
by nuclear transfer cloning. Science 295, 1089–1092.
Lauwereys, M., Arbabi Ghahroudi, M., Desmyter, A., Kinne, J., Hölzer, W., De Genst,
E., Wyns, L., Muyldermans, S., 1998. Potent enzyme inhibitors derived from
dromedary heavy-chain antibodies. EMBO J. 17, 3512–3520.
Lavanchy, D., 2005. Worldwide epidemiology of HBV infection, disease burden, and
vaccine prevention. J. Clin. Virol 34 (Suppl. 1), S1–S3.
Lavanchy, D., 2008. Chronic viral hepatitis as a public health issue in the world. Best.
Pract. Res. Clin. Gastroenterol. 22, 991–1008.
Ledeboer, A.M., Bezemer, S., de Hiaard, J.J.W., Schaffers, I.M., Verrips, C.T., van Vliet,
C., Düsterhöft, E.M., Zoon, P., Moineau, S., Frenken, L.G.J., 2002. Preventing phage
lysis of Lactococcus lactis in cheese production using a neutralizing heavy-chain
antibody fragment from llama. J. Dairy Sci. 85, 1376–1382.
van der Linden, R.H., Frenken, L.G., de Geus, B., Harmsen, M.M., Ruuls, R.C., Stok, W.,
de Ron, L., Wilson, S., Davis, P., Verrips, C.T., 1999. Comparison of physical
chemical properties of llama VHH antibody fragments and mouse monoclonal
antibodies. Biochim. Biophys. Acta 1431, 37–46.
Mai, K.T., Perkins, D.G., Zhang, J., Mackenzie, C.R., 2006. ES1, a new lung carcinoma
antibody – an immunohistochemical study. Histopathology 49, 515–522.
Malim, M.H., Hauber, J., Le, S.Y., Maizel, J.V., Cullen, B.R., 1989. The HIV-1 rev transactivator acts through a structured target sequence to activate nuclear export of
unspliced viral mRNA. Nature 338, 254–257.
Martín, M.C., Pant, N., Ladero, V., Günaydin, G., Andersen, K.K., Alvarez, B., Martínez,
N., Alvarez, M.A., Hammarström, L., Marcotte, H., 2011. Integrative expression
system for delivery of antibody fragments by lactobacilli. Appl. Environ.
Microbiol. 77, 2174–2179.
Moineau, S., 1999. Applications of phage resistance in lactic acid bacteria. Antonie
Van Leeuwenhoek 76, 377–382.
Moore, J.P., Trkola, A., Dragic, T., 1997. Co-receptors for HIV-1 entry. Curr. Opin.
Immunol. 9, 551–562.
Moulard, M., Phogat, S.K., Shu, Y., Labrijn, A.F., Xiao, X., Binley, J.M., Zhang, M.-Y.,
Sidorov, I.A., Broder, C.C., Robinson, J., Parren, P.W.H.I., Burton, D.R., Dimitrov,
D.S., 2002. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab
selected for binding to gp120–CD4–CCR5 complexes. Proc. Natl. Acad. Sci. USA
99, 6913–6918.
Muhamuda, K., Madhusudana, S.N., Ravi, V., 2007. Use of neutralizing murine
monoclonal antibodies to rabies glycoprotein in passive immunotherapy
against rabies. Hum. Vaccine 3, 192–195.
Müller, T., Dietzschold, B., Ertl, H., Fooks, A.R., Freuling, C., Fehlner-Gardiner, C.,
Kliemt, J., Meslin, F.X., Franka, R., Rupprecht, C.E., Tordo, N., Wanderler, A.I.,
Kieny, M.P., 2009. Development of a mouse monoclonal antibody cocktail
for post-exposure rabies prophylaxis in humans. PLoS Negl. Trop. Dis. 3,
e542.
Muyldermans, S., Atarhouch, T., Saldanha, J., Barbosa, J.A., Hamers, R., 1994.
Sequence and structure of VH domain from naturally occurring camel heavy
chain immunoglobulins lacking light chains. Protein Eng. 7, 1129–1135.
406
P. Vanlandschoot et al. / Antiviral Research 92 (2011) 389–407
Muyldermans, S., Cambillau, C., Wyns, L., 2001. Recognition of antigens by singledomain antibody fragments: the superfluous luxury of paired domains. Trends
Biochem. Sci. 26, 230–235.
Muyldermans, S., Baral, T.N., Retamozzo, V.C., De Baetselier, P., De Genst, E., Kinne, J.,
Leonhardt, H., Magez, S., Nguyen, V.K., Revets, H., Rothbauer, U., Stijlemans, B.,
Tillib, S., Wernery, U., Wyns, L., Hassanzadeh-Ghassabeh, G., Saerens, D., 2009.
Camelid immunoglobulins and nanobody technology. Vet. Immunol.
Immunopathol. 128, 178–183.
Neville, M., Stutz, F., Lee, L., Davis, L.I., Rosbash, M., 1997. The importin-beta family
member Crm1p bridges the interaction between Rev and the nuclear pore
complex during nuclear export. Curr. Biol. 7, 767–775.
Nguyen, V.K., Hamers, R., Wyns, L., Muyldermans, S., 1999. Loss of splice consensus
signal is responsible for the removal of the entire C(H)1 domain of the
functional camel IGG2A heavy-chain antibodies. Mol. Immunol. 36, 515–524.
Nguyen, V.K., Hamers, R., Wyns, L., Muyldermans, S., 2000. Camel heavy-chain
antibodies: diverse germline V(H)H and specific mechanisms enlarge the
antigen-binding repertoire. EMBO J. 19, 921–930.
Nuttall, S.D., Krishnan, U.V., Hattarki, M., De Gori, R., Irving, R.A., Hudson, P.J.,
2001. Isolation of the new antigen receptor from wobbegong sharks, and use
as a scaffold for the display of protein loop libraries. Mol. Immunol. 38,
313–326.
Pant, N., Hultberg, A., Zhao, Y., Svensson, L., Pan-Hammarstrom, Q., Johansen, K.,
Pouwels, P.H., Ruggeri, F.M., Hermans, P., Frenken, L., Boren, T., Marcotte, H.,
Hammarstrom, L., 2006. Lactobacilli expressing variable domain of llama
heavy-chain antibody fragments (lactobodies) confer protection against
rotavirus-induced diarrhea. J. Infect. Dis. 194, 1580–1588.
Paradis, K., Langford, G., Long, Z., Heneine, W., Sandstrom, P., Switzer, W.M.,
Chapman, L.E., Lockey, C., Onions, D., Otto, E., 1999. Search for cross-species
transmission of porcine endogenous retrovirus in patients treated with living
pig tissue. The XEN 111 Study Group. Science 285, 1236–1241.
Parashar, U.D., Gibson, C.J., Bresse, J.S., Glass, R.I., 2006. Rotavirus and severe
childhood diarrhea. Emerging Infect. Dis. 12, 304–306.
Patience, C., Takeuchi, Y., Weiss, R.A., 1997. Infection of human cells by an
endogenous retrovirus of pigs. Nat. Med. 3, 282–286.
Patience, C., Switzer, W.M., Takeuchi, Y., Griffiths, D.J., Goward, M.E., Heneine, W.,
Stoye, J.P., Weiss, R.A., 2001. Multiple groups of novel retroviral genomes in pigs
and related species. J. Virol. 75, 2771–2775.
Pérez, J.M., Renisio, J.G., Prompers, J.J., van Platerink, C.J., Cambillau, C., Darbon, H.,
Frenken, L.G., 2001. Thermal unfolding of a llama antibody fragment: a twostate reversible process. Biochemistry 40, 74–83.
Peterson, A.T., Bauer, J.T., Mills, J.N., 2004. Ecologic and geographic distribution of
filovirus disease. Emerging Infect. Dis. 10, 40–47.
Phelps, C.J., Koike, C., Vaught, T.D., Boone, J., Wells, K.D., Chen, S.-H., Ball, S., Specht,
S.M., Polejaeva, I.A., Monahan, J.A., Jobst, P.M., Sharma, S.B., Lamborn, A.E., Garst,
A.S., Moore, M., Demetris, A.J., Rudert, W.A., Bottino, R., Bertera, S., Trucco, M.,
Starzl, T.E., Dai, Y., Ayares, D.L., 2003. Production of alpha 1,3galactosyltransferase-deficient pigs. Science 299, 411–414.
Platt, J.L., 2002. Knocking out xenograft rejection. Nat. Biotechnol. 20, 231–232.
Pollard, V.W., Malim, M.H., 1998. The HIV-1 Rev protein. Annu. Rev. Microbiol. 52,
491–532.
Prince, G.A., Hemming, V.G., Horswood, R.L., Chanock, R.M., 1985.
Immunoprophylaxis and immunotherapy of respiratory syncytial virus
infection in the cotton rat. Virus Res. 3, 193–206.
Rabe, B., Vlachou, A., Panté, N., Helenius, A., Kann, M., 2003. Nuclear import of
hepatitis B virus capsids and release of the viral genome. Proc. Natl. Acad. Sci.
USA 100, 9849–9854.
Roben, P., Moore, J.P., Thali, M., Sodroski, J., Barbas 3rd, C.F., Burton, D.R., 1994.
Recognition properties of a panel of human recombinant Fab fragments to the
CD4 binding site of gp120 that show differing abilities to neutralize human
immunodeficiency virus type 1. J. Virol. 68, 4821–4828.
Roovers, R.C., Laeremans, T., Huang, L., De Taeye, S., Verkleij, A.J., Revets, H., de
Haard, H.J., en Henegouwen, P.M.P., 2007. Efficient inhibition of EGFR signaling
and of tumour growth by antagonistic anti-EFGR Nanobodies. Cancer Immunol.
Immunother. 56, 303–317.
Russell, C.A., Jones, T.C., Barr, I.G., Cox, N.J., Garten, R.J., Gregory, V., Gust, I.D.,
Hampson, A.W., Hay, A.J., Hurt, A.C., de Jong, J.C., Kelso, A., Klimov, A.I.,
Kageyama, T., Komadina, N., Lapedes, A.S., Lin, Y.P., Mosterin, A., Obuchi, M.,
Odagiri, T., Osterhaus, A.D.M.E., Rimmelzwaan, G.F., Shaw, M.W., Skepner, E.,
Stohr, K., Tashiro, M., Fouchier, R.A.M., Smith, D.J., 2008. The global circulation
of seasonal influenza A (H3N2) viruses. Science 320, 340–346.
Sanders, R.W., Venturi, M., Schiffner, L., Kalyanaraman, R., Katinger, H., Lloyd, K.O.,
Kwong, P.D., Moore, J.P., 2002. The mannose-dependent epitope for neutralizing
antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J.
Virol. 76, 7293–7305.
Sarker, S.A., Casswall, T.H., Juneja, L.R., Hoq, E., Hossain, I., Fuchs, G.J., Hammarström,
L., 2001. Randomized, placebo-controlled, clinical trial of hyperimmunized
chicken egg yolk immunoglobulin in children with rotavirus diarrhea. J. Pediatr.
Gastroenterol. Nutr. 32, 19–25.
Sawyer, L.A., 2000. Antibodies for the prevention and treatment of viral diseases.
Antiviral Res. 47, 57–77.
Serruys, B., Van Houtte, F., Farhoudi-Moghadam, A., Leroux-Roels, G.,
Vanlandschoot, P., 2010. Production, characterization and in vitro testing of
HBcAg-specific VHH intrabodies. J. Gen. Virol. 91, 643–652.
Serruys, B., Van Houtte, F., Verbrugghe, P., Leroux-Roels, G., Vanlandschoot, P., 2009.
Llama-derived single-domain intrabodies inhibit secretion of hepatitis B virions
in mice. Hepatology 49, 39–49.
Sherwood, L.J., Osborn, L.E., Carrion Jr., R., Patterson, J.L., Hayhurst, A., 2007. Rapid
assembly of sensitive antigen-capture assays for Marburg virus, using in vitro
selection of llama single-domain antibodies, at biosafety level 4. J. Infect. Dis.
196 (Suppl. 2), S213–S219.
Simoes, E.A., Groothuis, J.R., Tristram, D.A., Allessi, K., Lehr, M.V., Siber, G.R.,
Welliver, R.C., 1996. Respiratory syncytial virus-enriched globulin for the
prevention of acute otitis media in high risk children. J. Pediatr. 129,
214–219.
Specke, V., Rubant, S., Denner, J., 2001. Productive infection of human primary
cells and cell lines with porcine endogenous retroviruses. Virology 285,
177–180.
Spinelli, S., Desmyter, A., Verrips, C.T., de Haard, H.J.W., Moineau, S., Cambillau, C.,
2006. Lactococcal bacteriophage p2 receptor-binding protein structure suggests
a common ancestor gene with bacterial and mammalian viruses. Nat. Struct.
Mol. Biol. 13, 85–89.
Stewart, C.S., MacKenzie, C.R., Hall, J.C., 2007. Isolation, characterization and
pentamerization of alpha-cobrotoxin specific single-domain antibodies from a
naïve phage display library: preliminary findings for antivenom development.
Toxicon 49, 699–709.
Stijlemans, B., Caljon, G., Natesan, S.K.A., Saerens, D., Conrath, K., Pérez-Morga, D.,
Skepper, J.N., Nikolaou, A., Brys, L., Pays, E., Magez, S., Field, M.C., De Baetselier,
P., Muyldermans, S., 2011. High affinity nanobodies against the Trypanosome
brucei VSG are potent trypanolytic agents that block endocytosis. PLoS Pathog.
7, e1002072.
Stijlemans, B., Conrath, K., Cortez-Retamozo, V., Van Xong, H., Wyns, L., Senter, P.,
Revets, H., De Baetselier, P., Muyldermans, S., Magez, S., 2004. Efficient targeting
of conserved cryptic epitopes of infectious agents by single domain antibodies.
African trypanosomes as paradigm. J. Biol. Chem. 279, 1256–1261.
Stone, E., Hirama, T., Chen, W., Soltyk, A.L., Brunton, J., MacKenzie, C.R., Zhang, J.,
2007a. A novel pentamer versus pentamer approach to generating neutralizers
of verotoxin 1. Mol. Immunol. 44, 2487–2491.
Stone, E., Hirama, T., Tanha, J., Tong-Sevinc, H., Li, S., MacKenzie, C.R., Zhang, J.,
2007b. The assembly of single domain antibodies into bispecific decavalent
molecules. J. Immunol. Methods 318, 88–94.
Takeuchi, Y., Patience, C., Magre, S., Weiss, R.A., Banerjee, P.T., Le Tissier, P., Stoye,
J.P., 1998. Host range and interference studies of three classes of pig
endogenous retrovirus. J. Virol. 72, 9986–9991.
Taylor, G., Stott, E.J., Bew, M., Fernie, B.F., Cote, P.J., Collins, A.P., Hughes, M., Jebbett,
J., 1984. Monoclonal antibodies protect against respiratory syncytial virus
infection in mice. Immunology 52, 137–142.
Thys, B., Saerens, D., Schotte, L., De Bleeser, G., Muyldermans, S., HassanzadehGhassabeh, G., Rombaut, B., 2011. A simple quantitative affinity capturing assay
of poliovirus antigens and subviral particles by single-domain antibodies using
magnetic beads. J. Virol. Methods 173, 300–305.
Thys, B., Schotte, L., Muyldermans, S., Wernery, U., Hassanzadeh-Ghassabeh, G.,
Rombaut, B., 2010. In vitro antiviral activity of single domain antibody
fragments against poliovirus. Antiviral Res. 87, 257–264.
Tijink, B.M., Laeremans, T., Budde, M., Stigter-van Walsum, M., Dreier, T., de Haard,
H.J., Leemans, C.R., van Dongen, G.A.M.S., 2008. Improved tumor targeting of
anti-epidermal growth factor receptor Nanobodies through albumin binding:
taking advantage of modular Nanobody technology. Mol. Cancer Ther. 7,
2288–2297.
Le Tissier, P., Stoye, J.P., Takeuchi, Y., Patience, C., Weiss, R.A., 1997. Two sets of
human-tropic pig retrovirus. Nature 389, 681–682.
Transue, T.R., De Genst, E., Ghahroudi, M.A., Wyns, L., Muyldermans, S., 1998. Camel
single-domain antibody inhibits enzyme by mimicking carbohydrate substrate.
Proteins 32, 515–522.
Tremblay, D.M., Tegoni, M., Spinelli, S., Campanacci, V., Blangy, S., Huyghe, C.,
Desmyter, A., Labrie, S., Moineau, S., Cambillau, C., 2006. Receptor-binding
protein of Lactococcus lactis phages: identification and characterization of the
saccharide receptor-binding site. J. Bacteriol. 188, 2400–2410.
Trkola, A., Purtscher, M., Muster, T., Ballaun, C., Buchacher, A., Sullivan, N.,
Srinivasan, K., Sodroski, J., Moore, J.P., Katinger, H., 1996. Human monoclonal
antibody 2G12 defines a distinctive neutralization epitope on the gp120
glycoprotein of human immunodeficiency virus type 1. J. Virol. 70,
1100–1108.
van der Vaart, J.M., Pant, N., Wolvers, D., Bezemer, S., Hermans, P.W., Bellamy, K.,
Sarker, S.A., van der Logt, C.P.E., Svensson, L., Verrips, C.T., Hammarstrom, L., van
Klinken, B.J.W., 2006. Reduction in morbidity of rotavirus induced diarrhoea in
mice by yeast produced monovalent llama-derived antibody fragments. Vaccine
24, 4130–4137.
Vercruysse, T., Pardon, E., Vanstreels, E., Steyaert, J., Daelemans, D., 2010. An
intrabody based on a llama single-domain antibody targeting the N-terminal
alpha-helical multimerization domain of HIV-1 rev prevents viral production. J.
Biol. Chem. 285, 21768–21780.
Vercruysse, T., Pawar, S., De Borggraeve, W., Pardon, E., Pavlakis, G.N., Pannecouque,
C., Steyaert, J., Balzarini, J., Daelemans, D., 2011. Measuring cooperative Rev
protein-protein interactions on Rev responsive RNA by fluorescence resonance
energy transfer. RNA Biol. 8, 316–324.
Verheesen, P., Roussis, A., de Haard, H.J., Groot, A.J., Stam, J.C., den Dunnen, J.T.,
Frants, R.R., Verkleij, A.J., Theo Verrips, C., van der Maarel, S.M., 2006.
Reliable and controllable antibody fragment selections from Camelid
non-immune libraries for target validation. Biochim. Biophys. Acta 1764,
1307–1319.
Vincke, C., Loris, R., Saerens, D., Martinez-Rodriguez, S., Muyldermans, S., Conrath,
K., 2009. General strategy to humanize a camelid single-domain antibody and
P. Vanlandschoot et al. / Antiviral Research 92 (2011) 389–407
identification of a universal humanized nanobody scaffold. J. Biol. Chem. 284,
3273–3284.
Vu, K.B., Ghahroudi, M.A., Wyns, L., Muyldermans, S., 1997. Comparison of llama VH
sequences from conventional and heavy chain antibodies. Mol. Immunol. 34,
1121–1131.
Walsh, E.E., Schlesinger, J.J., Brandriss, M.W., 1984. Protection from respiratory
syncytial virus infection in cotton rats by passive transfer of monoclonal
antibodies. Infect. Immun. 43, 756–758.
Ward, R., 2009. Mechanisms of protection against rotavirus infection and disease.
Pediatr. Infect. Dis. J. 28, S57–59.
Wassilak, S., Orenstein, W., 2010. Challenges faced by the global polio eradication
initiative. Expert. Rev. Vaccines 9, 447–449.
Wesolowski, J., Alzogaray, V., Reyelt, J., Unger, M., Juarez, K., Urrutia, M., Cauerhff, A.,
Danquah, W., Rissiek, B., Scheuplein, F., Schwarz, N., Adriouch, S., Boyer, O.,
Seman, M., Licea, A., Serreze, D.V., Goldbaum, F.A., Haag, F., Koch-Nolte, F., 2009.
Single domain antibodies: promising experimental and therapeutic tools in
infection and immunity. Med. Microbiol. Immunol. 198, 157–174.
Woolven, B.P., Frenken, L.G., van der Logt, P., Nicholls, P.J., 1999. The structure of the
llama heavy chain constant genes reveals a mechanism for heavy-chain
antibody formation. Immunogenetics 50, 98–101.
407
Wu, H., Pfarr, D.S., Losonsky, G.A., Kiener, P.A., 2008. Immunoprophylaxis of RSV
infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr.
Top. Microbiol. Immunol. 317, 103–123.
Wyatt, R., Sodroski, J., 1998. The HIV-1 envelope glycoproteins: fusogens, antigens,
and immunogens. Science 280, 1884–1888.
Xu, R., Cai, K., Zheng, D., Ma, H., Xu, S., Fan, S.-T., 2003. Molecular therapeutics of
HBV. Curr. Gene Ther. 3, 341–355.
Yang, P.L., Althage, A., Chung, J., Chisari, F.V., 2002. Hydrodynamic injection of viral
DNA: a mouse model of acute hepatitis B virus infection. Proc. Natl. Acad. Sci.
USA 99, 13825–13830.
Zhang, J., Tanha, J., Hirama, T., Khieu, N.H., To, R., Tong-Sevinc, H., Stone, E., Brisson,
J.R., MacKenzie, C.R., 2004. Pentamerization of single-domain antibodies from
phage libraries: a novel strategy for the rapid generation of high-avidity
antibody reagents. J. Mol. Biol. 335, 49–56.
Zhou, T., Xu, L., Dey, B., Hessell, A.J., Van Ryk, D., Xiang, S.-H., Yang, X., Zhang, M.-Y.,
Zwick, M.B., Arthos, J., Burton, D.R., Dimitrov, D.S., Sodroski, J., Wyatt, R., Nabel,
G.J., Kwong, P.D., 2007. Structural definition of a conserved neutralization
epitope on HIV-1 gp120. Nature 445, 732–737.
Zoulim, F., 2011. Hepatitis B virus resistance to antiviral drugs: where are we going?
Liver. Int. 31 (Suppl. 1), 111–116.